Query Query
Results
Date
12 substances in Reaxys
2016-06-01 12h:59m:07s (EST)
N
1. Query
NH
Search as: As drawn
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
1/45
2016-06-01 13:02:51
Reaxys ID 138259 View in Reaxys
1/12 CAS Registry Number: 61-50-7 Chemical Name: N,N-dimethyltryptamine; N,N-Dimethyltryptamine; DMT; 2-(1H-indol-3-yl)-N,N-dimethylethan-1-amine; 2(1H-indol-3-yl)-N,N-dimethylethanamine; [2-(1H-indol-3-yl)-ethyl]-dimethylamine; 3-(2-dimethylaminoethyl)-1H-indole Linear Structure Formula: CH2C11H14N2 Molecular Formula: C12H16N2 Molecular Weight: 188.272 Type of Substance: heterocyclic InChI Key: DMULVCHRPCFFGV-UHFFFAOYSA-N Note:
N
NH
Substance Label (23) Label References 8e
Olsen, Elisabeth K.; Hansen, Espen; Moodie, Lindon W. K.; Isaksson, Johan; Sepi, Kristina; Cergolj, Marija; Svenson, Johan; Andersen, Jeanette H.; Organic and Biomolecular Chemistry; vol. 14; nb. 5; (2016); p. 1629 - 1640, View in Reaxys
DMT
Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J.; Journal of Pharmacology and Experimental Therapeutics; vol. 306; nb. 1; (2003); p. 73 - 83, View in Reaxys; Chu, Uyen B.; Vorperian, Sevahn K.; Satyshur, Kenneth; Eickstaedt, Kelsey; Cozzi, Nicholas V.; Mavlyutov, Timur; Hajipour, Abdol R.; Ruoho, Arnold E.; Biochemistry; vol. 53; nb. 18; (2014); p. 2956 - 2965, View in Reaxys; Calvert, Matthew B.; Sperry, Jonathan; Chemical Communications; vol. 51; nb. 28; (2015); p. 6202 - 6205, View in Reaxys
6d
Bartolucci, Silvia; Mari, Michele; Bedini, Annalida; Piersanti, Giovanni; Spadoni, Gilberto; Journal of Organic Chemistry; vol. 80; nb. 6; (2015); p. 3217 - 3222, View in Reaxys
2o
Tong, Shuo; Xu, Zhengren; Mamboury, Mathias; Wang, Qian; Zhu, Jieping; Angewandte Chemie - International Edition; vol. 54; nb. 40; (2015); p. 11809 - 11812; Angew. Chem.; vol. 127; nb. 40; (2015); p. 11975 11978,4, View in Reaxys
9
He, Yi; Li, Xiaolong; Li, Jue; Li, Xiaocen; Guo, Li; Hai, Li; Wu, Yong; Tetrahedron Letters; vol. 55; nb. 29; (2014); p. 3938 - 3941, View in Reaxys
5
Qu, Shi-Jin; Liu, Quan-Wen; Tan, Chang-Heng; Jiang, Shan-Hao; Zhu, Da-Yuan; Planta Medica; vol. 72; nb. 3; (2006); p. 264 - 266, View in Reaxys; Nyandege, Abner; Kolanos, Renata; Roth, Bryan L.; Glennon, Richard A.; Bioorganic and Medicinal Chemistry Letters; vol. 17; nb. 6; (2007); p. 1691 - 1694, View in Reaxys; Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Casale, Rosario; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 61; nb. 21; (2013); p. 5156 - 5162, View in Reaxys
KD38
Patent; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; OZPOLAT, Bulent; LOPEZ-BERESTEIN, Gabriel; DALBY, Kevin N.; JOSE, Jiney; WO2013/63492; (2013); (A1) English, View in Reaxys
4
Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 60; nb. 37; (2012); p. 9512 - 9518,7, View in Reaxys; Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 60; nb. 37; (2012); p. 9512 - 9518, View in Reaxys
1
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys
13; DMT
Parker, Matthew A.; Kurrasch, Deborah M.; Nichols, David E.; Bioorganic and Medicinal Chemistry; vol. 16; nb. 8; (2008); p. 4661 - 4669, View in Reaxys
2c
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 3865, View in Reaxys
3
Buchanan, Malcolm S.; Carroll, Anthony R.; Pass, David; Quinn, Ronald J.; Magnetic Resonance in Chemistry; vol. 45; nb. 4; (2007); p. 359 - 361, View in Reaxys
18
Kolanos, Renata; Dukat, Malgorzata; Roth, Bryan L.; Glennon, Richard A.; Bioorganic and Medicinal Chemistry Letters; vol. 16; nb. 22; (2006); p. 5832 - 5835, View in Reaxys
8a
Schmidt, Axel M.; Eilbracht, Peter; Journal of Organic Chemistry; vol. 70; nb. 14; (2005); p. 5528 - 5535, View in Reaxys
7
Dukat, Malgorzata; Smith, Carol; Herrick-Davis, Katharine; Teitler, Milt; Glennon, Richard A.; Bioorganic and Medicinal Chemistry; vol. 12; nb. 10; (2004); p. 2545 - 2552, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
2/45
2016-06-01 13:02:51
11a
Barluenga, Jose; Fananas, Francisco J.; Sanz, Roberto; Fernandez, Yolanda; Chemistry - A European Journal; vol. 8; nb. 9; (2002); p. 2034 - 2046, View in Reaxys
6e
Somei; Yamada; Kurauchi; Nagahama; Hasegawa; Teranishi; Sato; Kaneko; Chemical and Pharmaceutical Bulletin; vol. 49; nb. 1; (2001); p. 87 - 96, View in Reaxys
N,N-DMT
Bunzow; Sonders; Arttamangkul; Harrison; Zhang; Quigley; Darland; Suchland; Pasumamula; Kennedy; Olson; Magenis; Amara; Grandy; Molecular Pharmacology; vol. 60; nb. 6; (2001); p. 1181 - 1188, View in Reaxys
8
Lee, Tzong-Huei; Chou, Chang-Hung; Journal of the Chinese Chemical Society; vol. 47; nb. 6; (2000); p. 1287 - 1290, View in Reaxys
1a, DMT
Blair, Joseph B.; Marona-Lewicka, Danuta; Kanthasamy, Arthi; Lucaites, Virginia L.; Nelson, David L.; Nichols, David E.; Journal of Medicinal Chemistry; vol. 42; nb. 6; (1999); p. 1106 - 1111, View in Reaxys
4, DMT
Haefelinger, Guenter; Nimtz, Manfred; Horstmann, Volker; Benz, Thomas; Zeitschrift fur Naturforschung Section B Journal of Chemical Sciences; vol. 54; nb. 3; (1999); p. 397 - 414, View in Reaxys
11
Glennon, Richard A.; Bondarev, Mikhail; Roth, Bryan; Medicinal Chemistry Research; vol. 9; nb. 2; (1999); p. 108 - 117, View in Reaxys
2
Hong; Dukat; Teitler; Egan; Dupre; Herrick-Davis; Glennon; Medicinal Chemistry Research; vol. 9; nb. 6; (1999); p. 374 - 388, View in Reaxys
Patent-Specific Data (6) Prophetic ComLocation in Patent References pound Patent; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; OZPOLAT, Bulent; LOPEZ-BERESTEIN, Gabriel; DALBY, Kevin N.; JOSE, Jiney; WO2013/63492; (2013); (A1) English, View in Reaxys Patent; Suven Pharmaceuticals Ltd.; WO2004/205; (2003); (A2) English, View in Reaxys Patent; SUVEN PHARMACEUTICALS LTD.; WO2004/845; (2003); (A1) English, View in Reaxys Claim
Patent; Strahilevitz; Meir; US4620977; (1986); (A1) English, View in Reaxys; Patent; Wilburn, Michael D.; US2003/78231; (2003); (A1) English, View in Reaxys; Patent; Psychiatric Genomics, Inc.; US2003/82802; (2003); (A1) English, View in Reaxys; Patent; Wilburn, Michael D.; US2003/7961; (2003); (A1) English, View in Reaxys Patent; SUVEN PHARMACEUTICALS LTD.; WO2004/849; (2003); (A2) English, View in Reaxys
prophetic product Derivative (23) Comment (Derivative)
Patent; Eli Lilly and Company; US5096908; (1992); (A1) English, View in Reaxys Derivative
References
N,N-Dimethyltryptamine oxalate
Sintas, Jose A.; Vitale, Arturo A.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 39; nb. 8; (1997); p. 677 - 684, View in Reaxys
Pikrat: F: 167-168grad; MS
Ueno et al.; Chemical and Pharmaceutical Bulletin; vol. 26; (1978); p. 2411,2415, View in Reaxys
Pikrat: F: 168-170grad
Ghosal; Singh; Bhattacharya; Planta medica; vol. 19; nb. 3; (1971); p. 280 - 284, View in Reaxys; Wenkert; Kryger; Journal of the Indian Chemical Society; vol. 55; (1978); p. 1122, View in Reaxys; Marini-Bettolo et al.; Annali di Chimica (Rome, Italy); vol. 54; (1964); p. 1179,1185, View in Reaxys
Pikrat: Prep.: Tryptamin 4a, Pikrinsaeure; F: 168-170grad
Wenkert; Kryger; Journal of the Indian Chemical Society; vol. 55; (1978); p. 1122, View in Reaxys
Charge-TransferKomplex m. Hematoporphyrin: K(c) (Tab. 1)
Brucato et al.; Arzneimittel Forschung; vol. 27; (1977); p. 1015,1017, View in Reaxys
Pikrat: F: 166grad
Julia,M. et al.; Bulletin de la Societe Chimique de France; (1973); p. 1424 - 1426, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
3/45
2016-06-01 13:02:51
Pikrat: F: 168grad; gelb
Ghosal et al.; Planta Medica; vol. 21; (1972); p. 22,23, View in Reaxys
Hydrobromid: F: 114.5grad; Roentgenstrukturanalyse: Molekuel- u. Kristallstruktur
Falkenberg; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 28; (1972); p. 3075, View in Reaxys
Pikrat: F: 166-167grad; gelblich-orange
Ghosal et al.; Journal of Pharmaceutical Sciences; vol. 60; (1971); p. 1209,1211, View in Reaxys
Methoiodid: F: 216grad
Ghosal et al.; Journal of Pharmaceutical Sciences; vol. 60; (1971); p. 1209,1211, View in Reaxys
Pikrat: F: 160-168grad
Corothie; Nakano; Planta Medica; vol. 17; (1969); p. 184,186, View in Reaxys
Methoiodid: F: 197-198grad
Corothie; Nakano; Planta Medica; vol. 17; (1969); p. 184,186, View in Reaxys
Pikrat C12H16N2*C6H3 N3O7: F: 169grad; gelb
Rovelli; Vaughan; Australian Journal of Chemistry; vol. 20; (1967); p. 1299, View in Reaxys
Pikrat: F: 168-169grad
Dutta; Ghosal; Chemistry and Industry (London, United Kingdom); (1967); p. 2046, View in Reaxys
Oxalat C12H16N2*C2H2 O4: F: 147grad (Me., unkorr.)
Morimoto; Matsumoto; Justus Liebigs Annalen der Chemie; vol. 692; (1966); p. 194,197, View in Reaxys
Pikrat C12H16N2*C6H3 N3O7: F: 169grad (Me., unkorr.)
Morimoto; Matsumoto; Justus Liebigs Annalen der Chemie; vol. 692; (1966); p. 194,197, View in Reaxys
Iodmethalat C12H16N2*CH3I: F: 207grad (Acn., Me./Ae., unkorr.)
Morimoto; Matsumoto; Justus Liebigs Annalen der Chemie; vol. 692; (1966); p. 194,197, View in Reaxys
Pikrat C12H16N2*C6H3 N3O7: F: 171-171.5grad (A.) (rot); F: 170-171grad (A.) (gelb)
Fitzgerald; Sioumis; Australian Journal of Chemistry; vol. 18; (1965); p. 433,434, View in Reaxys
Pikrat C12H16N2*C6H3 N3O7: F: 166grad (Zers.)
Morimoto et al.; Justus Liebigs Annalen der Chemie; vol. 682; (1965); p. 212,218, View in Reaxys
Pikrat: F: 168grad
Ghosal; Mukherjee; Chemistry and Industry (London, United Kingdom); (1964); p. 1800, View in Reaxys
Pikrat C12H16N2*C6H3 N3O7: F: 169grad (A.); orange
Culvenor et al.; Australian Journal of Chemistry; vol. 17; (1964); p. 1301,1304, View in Reaxys
Methoiodid: Hofmannabbau -> 9percent monomeres, Rest polymeres 3-Vinyl-indol m. F: 160-175grad
Noland; Sundberg; Journal of Organic Chemistry; vol. 28; (1963); p. 884, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
4/45
2016-06-01 13:02:51
Pikrat: F: 170grad
Bodendorf; Walk; Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft; vol. 294; (1961); p. 484,487, View in Reaxys
Melting Point (27) 1 of 27
Melting Point [°C]
46 - 47
Solvent (Melting Point)
ethyl acetate; hexane
He, Yi; Li, Xiaolong; Li, Jue; Li, Xiaocen; Guo, Li; Hai, Li; Wu, Yong; Tetrahedron Letters; vol. 55; nb. 29; (2014); p. 3938 - 3941, View in Reaxys 2 of 27
Melting Point [°C]
45 - 47
Location
Page/Page column 33
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 3 of 27
Melting Point [°C]
64
Solvent (Melting Point)
hexane; ethyl acetate
Moura, Sidnei; Carvalho, Felipe Garcia; de Oliveira, Carolina Dizioli Rodrigues; Pinto, Ernani; Yonamine, Mauricio; Phytochemistry Letters; vol. 3; nb. 2; (2010); p. 79 - 83, View in Reaxys 4 of 27
Melting Point [°C]
38 - 40
Whitneys, Simon; Grigg, Ronald; Derrick, Andrew; Keep, Ann; Organic Letters; vol. 9; nb. 17; (2007); p. 3299 3302, View in Reaxys 5 of 27
Melting Point [°C]
45 - 47
Comment (Melting Point)
Method: distilled sample
Haefelinger, Guenter; Nimtz, Manfred; Horstmann, Volker; Benz, Thomas; Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences; vol. 54; nb. 3; (1999); p. 397 - 414, View in Reaxys 6 of 27
Melting Point [°C]
44 - 45
Sintas, Jose A.; Vitale, Arturo A.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 39; nb. 8; (1997); p. 677 - 684, View in Reaxys 7 of 27
Melting Point [°C]
46
Fleming,I.; Woolias,M.; Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999); (1979); p. 829 - 837, View in Reaxys 8 of 27
Melting Point [°C]
48 - 49
Ueno et al.; Chemical and Pharmaceutical Bulletin; vol. 26; (1978); p. 2411,2415, View in Reaxys 9 of 27
Melting Point [°C]
45 - 47
Wenkert; Kryger; Journal of the Indian Chemical Society; vol. 55; (1978); p. 1122, View in Reaxys 10 of 27
Melting Point [°C]
45
Julia,M. et al.; Bulletin de la Societe Chimique de France; (1973); p. 1424 - 1426, View in Reaxys 11 of 27
Melting Point [°C]
65.5
Falkenberg; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 28; (1972); p. 3075, View in Reaxys 12 of 27
Melting Point [°C]
57
Poissan; Annales Pharmaceutiques Francaises; vol. 23; (1965); p. 241, View in Reaxys; Kan-Fan et al.; Phytochemistry (Elsevier); vol. 9; (1970); p. 1283,1289, View in Reaxys 13 of 27
Melting Point [°C]
58.2
Bergin et al.; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 24; (1968); p. 882, View in Reaxys 14 of 27
Melting Point [°C]
45 - 49
Hall; McCapra; Scott; Tetrahedron; vol. 23; nb. 10; (1967); p. 4131 - 4141, View in Reaxys 15 of 27
Melting Point [°C]
44
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
5/45
2016-06-01 13:02:51
Solvent (Melting Point)
petroleum ether
Rovelli; Vaughan; Australian Journal of Chemistry; vol. 20; (1967); p. 1299, View in Reaxys 16 of 27
Melting Point [°C]
53.5 - 57.5
Solvent (Melting Point)
hexane
Arthur et al.; Australian Journal of Chemistry; vol. 20; (1967); p. 811,812, View in Reaxys 17 of 27
Melting Point [°C]
49
Solvent (Melting Point)
petroleum ether
Morimoto et al.; Justus Liebigs Annalen der Chemie; vol. 682; (1965); p. 212,218, View in Reaxys; Morimoto; Matsumoto; Justus Liebigs Annalen der Chemie; vol. 692; (1966); p. 194,197, View in Reaxys 18 of 27
Melting Point [°C]
42 - 43
Noell,C.W.; Cheng,C.C.; Journal of Heterocyclic Chemistry; vol. 3; (1966); p. 5 - 8, View in Reaxys 19 of 27
Melting Point [°C]
57.5 - 58.5
Solvent (Melting Point)
hexane
Fitzgerald; Sioumis; Australian Journal of Chemistry; vol. 18; (1965); p. 433,434, View in Reaxys 20 of 27
Melting Point [°C]
46 - 47
Solvent (Melting Point)
hexane
Fitzgerald; Sioumis; Australian Journal of Chemistry; vol. 18; (1965); p. 433,434, View in Reaxys 21 of 27
Melting Point [°C]
47
Ghosal; Mukherjee; Chemistry and Industry (London, United Kingdom); (1964); p. 1800, View in Reaxys 22 of 27
Melting Point [°C]
46.5
Solvent (Melting Point)
petroleum ether
Culvenor et al.; Australian Journal of Chemistry; vol. 17; (1964); p. 1301,1304, View in Reaxys 23 of 27
Melting Point [°C]
47 - 48
Heinzelman; Szmuszkovicz; Progress in Drug Research; vol. 6; (1963); p. 75,76-150; Chem.Abstr.; vol. 60; nb. 13215b; (1964), View in Reaxys 24 of 27
Melting Point [°C]
48 - 49
Solvent (Melting Point)
diethyl ether; petroleum ether
Bodendorf; Walk; Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft; vol. 294; (1961); p. 484,487, View in Reaxys 25 of 27
Melting Point [°C]
48 - 49
Solvent (Melting Point)
hexane; diethyl ether
Pachter et al.; Journal of Organic Chemistry; vol. 24; (1959); p. 1285, View in Reaxys 26 of 27
Melting Point [°C]
73 - 74
Solvent (Melting Point)
hexane
Comment (Melting Point)
and :47 degreeC.-:49 degreeC.
Fish et al.; Journal of the American Chemical Society; vol. 78; (1956); p. 3668,3670, View in Reaxys 27 of 27
Melting Point [°C]
49 - 50
Solvent (Melting Point)
diethyl ether; petroleum ether
Hoshino; Shimodaira; Justus Liebigs Annalen der Chemie; vol. 520; (1935); p. 19,26, View in Reaxys Boiling Point (2) Boiling Point [°C] 160
Pressure (Boiling Point) [Torr]
References
0.6
Haefelinger, Guenter; Nimtz, Manfred; Horstmann, Volker; Benz, Thomas; Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences; vol. 54; nb. 3; (1999); p. 397 - 414, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
6/45
2016-06-01 13:02:51
80 - 135
0.03
Corothie; Nakano; Planta Medica; vol. 17; (1969); p. 184,186, View in Reaxys
Density (1) 1 of 1
Type (Density)
crystallographic
Bergin et al.; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 24; (1968); p. 882, View in Reaxys Chromatographic Data (1) Chromatographic References data HPLC (High performance liquid chromatography)
Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 60; nb. 37; (2012); p. 9512 - 9518, View in Reaxys
Conformation (1) Object of Investi- References gation Conformation
Culvenor,C.C.J.; Ham,N.S.; Australian Journal of Chemistry; vol. 27; (1974); p. 2191 - 2198, View in Reaxys
Crystal Phase (2) Description (Crys- Comment (Crystal References tal Phase) Phase) Crystal structure determination Crystal structure determination
Falkenberg; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 28; (1972); p. 3075, View in Reaxys .
Crystal Property Description (11) Colour & Other Location Properties
Bergin et al.; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 24; (1968); p. 882, View in Reaxys References
white
Olsen, Elisabeth K.; Hansen, Espen; Moodie, Lindon W. K.; Isaksson, Johan; Sepi, Kristina; Cergolj, Marija; Svenson, Johan; Andersen, Jeanette H.; Organic and Biomolecular Chemistry; vol. 14; nb. 5; (2016); p. 1629 - 1640, View in Reaxys
brown
Bartolucci, Silvia; Mari, Michele; Bedini, Annalida; Piersanti, Giovanni; Spadoni, Gilberto; Journal of Organic Chemistry; vol. 80; nb. 6; (2015); p. 3217 - 3222, View in Reaxys
colourless
supporting information
Tong, Shuo; Xu, Zhengren; Mamboury, Mathias; Wang, Qian; Zhu, Jieping; Angewandte Chemie - International Edition; vol. 54; nb. 40; (2015); p. 11809 - 11812; Angew. Chem.; vol. 127; nb. 40; (2015); p. 11975 - 11978,4, View in Reaxys
brown
supporting information
He, Yi; Li, Xiaolong; Li, Jue; Li, Xiaocen; Guo, Li; Hai, Li; Wu, Yong; Tetrahedron Letters; vol. 55; nb. 29; (2014); p. 3938 - 3941, View in Reaxys
yellow
Paragraph 0509
Patent; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; OZPOLAT, Bulent; LOPEZ-BERESTEIN, Gabriel; DALBY, Kevin N.; JOSE, Jiney; WO2013/63492; (2013); (A1) English, View in Reaxys
colourless
light-yellow
Qu, Shi-Jin; Wang, Gui-Feng; Duan, Wen-Hu; Yao, Shan-Yan; Zuo, Jian-Ping; Tan, Chang-Heng; Zhu, Da-Yuan; Bioorganic and Medicinal Chemistry; vol. 19; nb. 10; (2011); p. 3120 - 3127, View in Reaxys Page/Page column 33
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys
white
Moura, Sidnei; Carvalho, Felipe Garcia; de Oliveira, Carolina Dizioli Rodrigues; Pinto, Ernani; Yonamine, Mauricio; Phytochemistry Letters; vol. 3; nb. 2; (2010); p. 79 83, View in Reaxys
yellow
Barluenga, Jose; Fananas, Francisco J.; Sanz, Roberto; Fernandez, Yolanda; Chemistry - A European Journal; vol. 8; nb. 9; (2002); p. 2034 - 2046, View in Reaxys Ghosal et al.; Planta Medica; vol. 21; (1972); p. 22,23, View in Reaxys; Ghosal et al.; Journal of Pharmaceutical Sciences; vol. 60; (1971); p. 1209,1211, View in Reaxys
dimorph
Fish et al.; Journal of the American Chemical Society; vol. 78; (1956); p. 3668,3670, View in Reaxys
Crystal System (1) References
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
7/45
2016-06-01 13:02:51
Bergin et al.; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 24; (1968); p. 882, View in Reaxys Dissociation Exponent (1) 1 of 1
Comment (Dissociation Exponent)
(pk')pK(a)
Glennon; Gessner; Journal of Medicinal Chemistry; vol. 22; (1979); p. 428,430, View in Reaxys Further Information (7) Description (Fur- References ther Information) Further information
Brucato et al.; Arzneimittel Forschung; vol. 27; (1977); p. 1015,1017, View in Reaxys
Further information
Banerjee; Ghosal; Australian Journal of Chemistry; vol. 22; (1969); p. 275, View in Reaxys
Further information
Ghosal; Banerjee; Australian Journal of Chemistry; vol. 22; (1969); p. 2029, View in Reaxys
Further information
Morimoto; Matsumoto; Justus Liebigs Annalen der Chemie; vol. 692; (1966); p. 194,197, View in Reaxys
Further information
Noland; Sundberg; Journal of Organic Chemistry; vol. 28; (1963); p. 884, View in Reaxys
Further information
Pecher et al.; Tetrahedron Letters; (1961); p. 270,272, View in Reaxys
Further information
Cohen et al.; Journal of the American Chemical Society; vol. 82; (1960); p. 2184, View in Reaxys
Ionization Potential (1) Ionization Poten- Comment (Ioniza- References tial [eV] tion Potential) 7.57
Type: vertical. Higher potentials: 8, 8.22, 9.54,
Kline; Benington; Morin; Beaton; Glennon; Domelsmith; Houk; Rozeboom; Journal of Medicinal Chemistry; vol. 25; nb. 11; (1982); p. 1381 - 1383, View in Reaxys
Other Thermochemical Data (1) Description (Oth- References er Thermochemical Data) Enthalpy
Gasco; Farmaco, Edizione Scientifica; vol. 30; (1975); p. 512,513, View in Reaxys
Solubility (MCS) (1) 1 of 1
Comment (Solubility (MCS))
In Ae. l.
Culvenor et al.; Australian Journal of Chemistry; vol. 17; (1964); p. 1301,1304, View in Reaxys Space Group (1) References Bergin et al.; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 24; (1968); p. 882, View in Reaxys NMR Spectroscopy (29) 1 of 29
Description (NMR Spec- Chemical shifts; Spectrum troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- d(4)-methanol scopy) Frequency (NMR Spectroscopy) [MHz]
600
Olsen, Elisabeth K.; Hansen, Espen; Moodie, Lindon W. K.; Isaksson, Johan; Sepi, Kristina; Cergolj, Marija; Svenson, Johan; Andersen, Jeanette H.; Organic and Biomolecular Chemistry; vol. 14; nb. 5; (2016); p. 1629 1640, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
8/45
2016-06-01 13:02:51
2 of 29
Description (NMR Spec- Chemical shifts; Spectrum troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- d(4)-methanol scopy) Frequency (NMR Spectroscopy) [MHz]
151
Olsen, Elisabeth K.; Hansen, Espen; Moodie, Lindon W. K.; Isaksson, Johan; Sepi, Kristina; Cergolj, Marija; Svenson, Johan; Andersen, Jeanette H.; Organic and Biomolecular Chemistry; vol. 14; nb. 5; (2016); p. 1629 1640, View in Reaxys 3 of 29
Description (NMR Spec- Chemical shifts; Spectrum troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
400
Location
supporting information
He, Yi; Li, Xiaolong; Li, Jue; Li, Xiaocen; Guo, Li; Hai, Li; Wu, Yong; Tetrahedron Letters; vol. 55; nb. 29; (2014); p. 3938 - 3941, View in Reaxys; Bartolucci, Silvia; Mari, Michele; Bedini, Annalida; Piersanti, Giovanni; Spadoni, Gilberto; Journal of Organic Chemistry; vol. 80; nb. 6; (2015); p. 3217 - 3222, View in Reaxys 4 of 29
Description (NMR Spec- Chemical shifts; Spectrum troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
400.1
Location
supporting information
Tong, Shuo; Xu, Zhengren; Mamboury, Mathias; Wang, Qian; Zhu, Jieping; Angewandte Chemie - International Edition; vol. 54; nb. 40; (2015); p. 11809 - 11812; Angew. Chem.; vol. 127; nb. 40; (2015); p. 11975 - 11978,4, View in Reaxys 5 of 29
Description (NMR Spec- Chemical shifts; Spectrum troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
100.6
Location
supporting information
Tong, Shuo; Xu, Zhengren; Mamboury, Mathias; Wang, Qian; Zhu, Jieping; Angewandte Chemie - International Edition; vol. 54; nb. 40; (2015); p. 11809 - 11812; Angew. Chem.; vol. 127; nb. 40; (2015); p. 11975 - 11978,4, View in Reaxys 6 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- dimethylsulfoxide-d6 scopy)
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
9/45
2016-06-01 13:02:51
Frequency (NMR Spectroscopy) [MHz]
100
Location
supporting information
He, Yi; Li, Xiaolong; Li, Jue; Li, Xiaocen; Guo, Li; Hai, Li; Wu, Yong; Tetrahedron Letters; vol. 55; nb. 29; (2014); p. 3938 - 3941, View in Reaxys 7 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
400
Original Text (NMR Spectroscopy)
XH (400 MHz CDC1 ) ? 8.47 (br, 1H), 7.52 (d, J= 7.7 Hz, 1H), 7.21 (d, J= 7.9 Hz, 1H), 3 7.08 (t, J= 7.2 Hz, 1H), 7.02 (t, J= 7.2 Hz, 1H), 6.84 (br, 1H), 2.87 (t, J= 7.8 Hz, 2H), 2.58 (t, J= 7.8 Hz, 2H), 2.27 (s, 6H)
Location
Paragraph 0558
Patent; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; OZPOLAT, Bulent; LOPEZ-BERESTEIN, Gabriel; DALBY, Kevin N.; JOSE, Jiney; WO2013/63492; (2013); (A1) English, View in Reaxys 8 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
101
Original Text (NMR Spectroscopy)
13C (101 MHz CDC1 ) ? 136.36, 127.42, 121.83, 121.73, 1 19.09, 118.73, 113.90, 11 1.25, 3 60.49, 45.37, 23.60.
Location
Paragraph 0558
Patent; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; OZPOLAT, Bulent; LOPEZ-BERESTEIN, Gabriel; DALBY, Kevin N.; JOSE, Jiney; WO2013/63492; (2013); (A1) English, View in Reaxys 9 of 29
Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
400
Original Text (NMR Spectroscopy)
1H NMR (400 MHz, CDC13): δ 8.68 (s, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.21 (t, J = 1.1 Hz, 1H), 7.14 (t, J = 1.5 Hz, 1H), 6.97 (s, 1H), 3.00 (t, J = 1.5 Hz, 2H), 2.72 (t, J = 8.4 Hz, 2H), 2.40 (s, 6H).
Location
Page/Page column 54
Comment (NMR Spectroscopy)
Signals given
Patent; THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS; KOZIKOWSKI, Alan; KALIN, Jay, Hans; BUTLER, Kyle, Vincent; BERGMAN, Joel; HANCOCK, Wayne, W.; WO2012/106343; (2012); (A2) English, View in Reaxys 10 of 29
Description (NMR Spec- Chemical shifts; Spectrum troscopy) Nucleus (NMR Spectroscopy)
1H
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
10/45
2016-06-01 13:02:51
Solvents (NMR Spectro- [D3]acetonitrile; d(4)-methanol scopy) Seki, Takayuki; Fujiwara, Tomoya; Takeuchi, Yoshio; Journal of Fluorine Chemistry; vol. 132; nb. 3; (2011); p. 181 - 185, View in Reaxys 11 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
400
Qu, Shi-Jin; Wang, Gui-Feng; Duan, Wen-Hu; Yao, Shan-Yan; Zuo, Jian-Ping; Tan, Chang-Heng; Zhu, DaYuan; Bioorganic and Medicinal Chemistry; vol. 19; nb. 10; (2011); p. 3120 - 3127, View in Reaxys 12 of 29
Description (NMR Spec- DEPT (Distorsionless Enhancement by Polarisation Transfer); Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
100
Qu, Shi-Jin; Wang, Gui-Feng; Duan, Wen-Hu; Yao, Shan-Yan; Zuo, Jian-Ping; Tan, Chang-Heng; Zhu, DaYuan; Bioorganic and Medicinal Chemistry; vol. 19; nb. 10; (2011); p. 3120 - 3127, View in Reaxys 13 of 29
Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
300
Original Text (NMR Spectroscopy)
H NMR, δ: 10.43 (s, 1 H), 7.42-7.06 (m, 5 H), 2.68 (m, 4H), 2.26 (S, 6 H).
Location
Page/Page column 33
Comment (NMR Spectroscopy)
Signals given
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 14 of 29
Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- chloroform-d1 scopy) Original Text (NMR Spectroscopy)
13C
Location
Page/Page column 33
Comment (NMR Spectroscopy)
Signals given
NMR (CDCl3): δ 136.5, 124.3, 123.2, 121.2, 119.7, 117.6, 113.4, 111.1, 61.7, 41.2, 22.4.
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 15 of 29
Description (NMR Spec- Chemical shifts; Spectrum troscopy) Nucleus (NMR Spectroscopy)
1H
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
11/45
2016-06-01 13:02:51
Solvents (NMR Spectro- chloroform-d1 scopy) Temperature (NMR Spectroscopy) [°C]
24.84
Frequency (NMR Spectroscopy) [MHz]
300
Moura, Sidnei; Carvalho, Felipe Garcia; de Oliveira, Carolina Dizioli Rodrigues; Pinto, Ernani; Yonamine, Mauricio; Phytochemistry Letters; vol. 3; nb. 2; (2010); p. 79 - 83, View in Reaxys 16 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- CDCl3 scopy) Grina, Jonas A.; Ratcliff, Matthew R.; Stermitz, Frank R.; Journal of Organic Chemistry; vol. 47; nb. 13; (1982); p. 2648 - 2651, View in Reaxys; Sintas, Jose A.; Vitale, Arturo A.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 39; nb. 8; (1997); p. 677 - 684, View in Reaxys; Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 17 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- CDCl3 scopy) Grina, Jonas A.; Ratcliff, Matthew R.; Stermitz, Frank R.; Journal of Organic Chemistry; vol. 47; nb. 13; (1982); p. 2648 - 2651, View in Reaxys; Sintas, Jose A.; Vitale, Arturo A.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 39; nb. 8; (1997); p. 677 - 684, View in Reaxys; Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 18 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]
500
Whitneys, Simon; Grigg, Ronald; Derrick, Andrew; Keep, Ann; Organic Letters; vol. 9; nb. 17; (2007); p. 3299 3302, View in Reaxys 19 of 29
Description (NMR Spec- Spectrum troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]
500
Whitneys, Simon; Grigg, Ronald; Derrick, Andrew; Keep, Ann; Organic Letters; vol. 9; nb. 17; (2007); p. 3299 3302, View in Reaxys 20 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
12/45
2016-06-01 13:02:51
Solvents (NMR Spectro- dimethylsulfoxide-d6 scopy) Temperature (NMR Spectroscopy) [°C]
30
Frequency (NMR Spectroscopy) [MHz]
125
Buchanan, Malcolm S.; Carroll, Anthony R.; Pass, David; Quinn, Ronald J.; Magnetic Resonance in Chemistry; vol. 45; nb. 4; (2007); p. 359 - 361, View in Reaxys 21 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- dimethylsulfoxide-d6 scopy) Temperature (NMR Spectroscopy) [°C]
30
Frequency (NMR Spectroscopy) [MHz]
500
Buchanan, Malcolm S.; Carroll, Anthony R.; Pass, David; Quinn, Ronald J.; Magnetic Resonance in Chemistry; vol. 45; nb. 4; (2007); p. 359 - 361, View in Reaxys 22 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]
400
Barluenga, Jose; Fananas, Francisco J.; Sanz, Roberto; Fernandez, Yolanda; Chemistry - A European Journal; vol. 8; nb. 9; (2002); p. 2034 - 2046, View in Reaxys 23 of 29
Nucleus (NMR Spectroscopy)
1H
Coupling Nuclei
1H
Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]
400
Barluenga, Jose; Fananas, Francisco J.; Sanz, Roberto; Fernandez, Yolanda; Chemistry - A European Journal; vol. 8; nb. 9; (2002); p. 2034 - 2046, View in Reaxys 24 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]
50.5
Barluenga, Jose; Fananas, Francisco J.; Sanz, Roberto; Fernandez, Yolanda; Chemistry - A European Journal; vol. 8; nb. 9; (2002); p. 2034 - 2046, View in Reaxys 25 of 29
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
13/45
2016-06-01 13:02:51
Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]
90
Haefelinger, Guenter; Nimtz, Manfred; Horstmann, Volker; Benz, Thomas; Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences; vol. 54; nb. 3; (1999); p. 397 - 414, View in Reaxys 26 of 29
Description (NMR Spec- Spin-spin coupling constants troscopy) Solvents (NMR Spectro- CDCl3 scopy) Comment (NMR Spectroscopy)
1H-1H
Grina, Jonas A.; Ratcliff, Matthew R.; Stermitz, Frank R.; Journal of Organic Chemistry; vol. 47; nb. 13; (1982); p. 2648 - 2651, View in Reaxys 27 of 29
Description (NMR Spec- Spin-spin coupling constants troscopy) Culvenor,C.C.J.; Ham,N.S.; Australian Journal of Chemistry; vol. 27; (1974); p. 2191 - 2198, View in Reaxys
28 of 29
Description (NMR Spec- NMR troscopy) Hall et al.; Tetrahedron; vol. 23; (1967); p. 4131, View in Reaxys; Corothie; Nakano; Planta Medica; vol. 17; (1969); p. 184,186, View in Reaxys
29 of 29
Description (NMR Spec- Spectrum troscopy) Cohen et al.; Journal of the American Chemical Society; vol. 82; (1960); p. 2184, View in Reaxys
IR Spectroscopy (4) 1 of 4
Description (IR Spectroscopy)
Bands
Corothie; Nakano; Planta Medica; vol. 17; (1969); p. 184,186, View in Reaxys; Olsen, Elisabeth K.; Hansen, Espen; Moodie, Lindon W. K.; Isaksson, Johan; Sepi, Kristina; Cergolj, Marija; Svenson, Johan; Andersen, Jeanette H.; Organic and Biomolecular Chemistry; vol. 14; nb. 5; (2016); p. 1629 - 1640, View in Reaxys 2 of 4
Description (IR Spectroscopy)
Bands
Solvent (IR Spectroscopy)
film
Whitneys, Simon; Grigg, Ronald; Derrick, Andrew; Keep, Ann; Organic Letters; vol. 9; nb. 17; (2007); p. 3299 3302, View in Reaxys 3 of 4
Description (IR Spectroscopy)
Bands
Solvent (IR Spectroscopy)
neat (no solvent)
Comment (IR Spectroscopy)
3400 - 740 cm**(-1)
Grina, Jonas A.; Ratcliff, Matthew R.; Stermitz, Frank R.; Journal of Organic Chemistry; vol. 47; nb. 13; (1982); p. 2648 - 2651, View in Reaxys 4 of 4
Description (IR Spectroscopy)
IR
Hall; McCapra; Scott; Tetrahedron; vol. 23; nb. 10; (1967); p. 4131 - 4141, View in Reaxys; Morimoto; Matsumoto; Justus Liebigs Annalen der Chemie; vol. 692; (1966); p. 194,197, View in Reaxys Mass Spectrometry (13) Description (Mass Location Spectrometry)
References
high resolution mass spectrometry (HRMS); elec-
Olsen, Elisabeth K.; Hansen, Espen; Moodie, Lindon W. K.; Isaksson, Johan; Sepi, Kristina; Cergolj, Marija; Svenson, Johan; Andersen, Jeanette H.; Organic and Biomolecular Chemistry; vol. 14; nb. 5; (2016); p. 1629 - 1640, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
14/45
2016-06-01 13:02:51
trospray ionisation (ESI); spectrum electrospray ionisation (ESI); spectrum
Bartolucci, Silvia; Mari, Michele; Bedini, Annalida; Piersanti, Giovanni; Spadoni, Gilberto; Journal of Organic Chemistry; vol. 80; nb. 6; (2015); p. 3217 - 3222, View in Reaxys
electrospray ionisation (ESI); spectrum
supporting information
He, Yi; Li, Xiaolong; Li, Jue; Li, Xiaocen; Guo, Li; Hai, Li; Wu, Yong; Tetrahedron Letters; vol. 55; nb. 29; (2014); p. 3938 - 3941, View in Reaxys
electrospray ionisation (ESI); liquid chromatography mass spectrometry (LCMS); spectrum
Paragraph 0558
Patent; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; OZPOLAT, Bulent; LOPEZ-BERESTEIN, Gabriel; DALBY, Kevin N.; JOSE, Jiney; WO2013/63492; (2013); (A1) English, View in Reaxys
high resolution Paragraph 0558 mass spectrometry (HRMS); spectrum
Patent; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; OZPOLAT, Bulent; LOPEZ-BERESTEIN, Gabriel; DALBY, Kevin N.; JOSE, Jiney; WO2013/63492; (2013); (A1) English, View in Reaxys
liquid chromatography mass spectrometry (LCMS); electrospray ionisation (ESI); tandem mass spectrometry; spectrum
Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Casale, Rosario; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 61; nb. 21; (2013); p. 5156 - 5162, View in Reaxys
spectrum
Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 60; nb. 37; (2012); p. 9512 - 9518,7, View in Reaxys; Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 60; nb. 37; (2012); p. 9512 - 9518, View in Reaxys
ESI (Electrospray ionisation); Spectrum
Qu, Shi-Jin; Wang, Gui-Feng; Duan, Wen-Hu; Yao, Shan-Yan; Zuo, Jian-Ping; Tan, Chang-Heng; Zhu, Da-Yuan; Bioorganic and Medicinal Chemistry; vol. 19; nb. 10; (2011); p. 3120 - 3127, View in Reaxys
ESI (Electrospray ionisation); HRMS (High resolution mass spectrometry); Spectrum
Qu, Shi-Jin; Wang, Gui-Feng; Duan, Wen-Hu; Yao, Shan-Yan; Zuo, Jian-Ping; Tan, Chang-Heng; Zhu, Da-Yuan; Bioorganic and Medicinal Chemistry; vol. 19; nb. 10; (2011); p. 3120 - 3127, View in Reaxys
LCMS (Liquid chromatography mass spectrometry); ESI (Electrospray ionisation); Spectrum
Moura, Sidnei; Carvalho, Felipe Garcia; de Oliveira, Carolina Dizioli Rodrigues; Pinto, Ernani; Yonamine, Mauricio; Phytochemistry Letters; vol. 3; nb. 2; (2010); p. 79 83, View in Reaxys
spectrum; electron impact (EI)
Sintas, Jose A.; Vitale, Arturo A.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 39; nb. 8; (1997); p. 677 - 684, View in Reaxys; Barluenga, Jose; Fananas, Francisco J.; Sanz, Roberto; Fernandez, Yolanda; Chemistry - A European Journal; vol. 8; nb. 9; (2002); p. 2034 - 2046, View in Reaxys
electron impact (EI); spectrum
Grina, Jonas A.; Ratcliff, Matthew R.; Stermitz, Frank R.; Journal of Organic Chemistry; vol. 47; nb. 13; (1982); p. 2648 - 2651, View in Reaxys Hall; McCapra; Scott; Tetrahedron; vol. 23; nb. 10; (1967); p. 4131 - 4141, View in Reaxys; Poissan; Annales Pharmaceutiques Francaises; vol. 23; (1965); p. 241, View in Reaxys; Bellman; Journal - Association of Official Analytical Chemists; vol. 51; (1968); p. 164,169, View in Reaxys; Corothie; Nakano; Planta Medica; vol. 17; (1969); p. 184,186, View in Reaxys; Ueno et al.; Chemical and Pharmaceutical Bulletin; vol. 26; (1978); p. 2411,2415, View in Reaxys
UV/VIS Spectroscopy (6) 1 of 6
Description (UV/VIS Spectroscopy)
Spectrum
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
15/45
2016-06-01 13:02:51
Solvent (UV/VIS Spectroscopy)
gaseous matrix
Comment (UV/VIS Spectroscopy)
283.5 - 288 nm
Li, Liang; Lubman, David M.; Analytical Chemistry; vol. 60; nb. 23; (1988); p. 2591 - 2598, View in Reaxys 2 of 6
Description (UV/VIS Spectroscopy)
Absorption maxima
Solvent (UV/VIS Spectroscopy)
ethanol
Absorption Maxima (UV/ 293; 284; 279; 226 VIS) [nm] Grina, Jonas A.; Ratcliff, Matthew R.; Stermitz, Frank R.; Journal of Organic Chemistry; vol. 47; nb. 13; (1982); p. 2648 - 2651, View in Reaxys 3 of 6
Description (UV/VIS Spectroscopy)
UV/VIS
Dutta; Ghosal; Chemistry and Industry (London, United Kingdom); (1967); p. 2046, View in Reaxys; Hall et al.; Tetrahedron; vol. 23; (1967); p. 4131, View in Reaxys; Wenkert; Kryger; Journal of the Indian Chemical Society; vol. 55; (1978); p. 1122, View in Reaxys; Ghosal et al.; Journal of Pharmaceutical Sciences; vol. 60; (1971); p. 1209,1211, View in Reaxys; Aaron et al.; Clinica Chimica Acta; vol. 45; (1973); p. 375,379, View in Reaxys; Corothie; Nakano; Planta Medica; vol. 17; (1969); p. 184,186, View in Reaxys; Ueno et al.; Chemical and Pharmaceutical Bulletin; vol. 26; (1978); p. 2411,2415, View in Reaxys 4 of 6
Description (UV/VIS Spectroscopy)
Absorption maxima
Ghosal et al.; Planta Medica; vol. 21; (1972); p. 22,23, View in Reaxys; Jackson; Smith; Journal of the Chemical Society; (1964); p. 5510,5511, View in Reaxys; Ghosal; Singh; Bhattacharya; Planta medica; vol. 19; nb. 3; (1971); p. 280 - 284, View in Reaxys; Poissan; Annales Pharmaceutiques Francaises; vol. 23; (1965); p. 241, View in Reaxys 5 of 6
Description (UV/VIS Spectroscopy)
Spectrum
Ghosal; Mukherjee; Chemistry and Industry (London, United Kingdom); (1964); p. 1800, View in Reaxys 6 of 6
Description (UV/VIS Spectroscopy)
Absorption maxima
Solvent (UV/VIS Spectroscopy)
ethanol
Absorption Maxima (UV/ 274; 283; 291 VIS) [nm] Fish et al.; Journal of the American Chemical Society; vol. 77; (1955); p. 5892,5895, View in Reaxys Luminescence Spectroscopy (1) Description (LuReferences minescence Spectroscopy) Luminescence quenching
Bowd et al.; Photochemistry and Photobiology; vol. 11; (1970); p. 445,447, View in Reaxys
Fluorescence Spectroscopy (2) Description (Fluo- Solvent (Fluoresrescence Speccence Spectrotroscopy) scopy)
Comment (Fluorescence Spectroscopy)
Fluorescence
Maxima
References
Bridges; Williams; Biochemical Journal; vol. 107; (1968); p. 225,228, View in Reaxys; Aaron et al.; Clinica Chimica Acta; vol. 45; (1973); p. 375,379, View in Reaxys ethanol
350 nm
Fish et al.; Journal of the American Chemical Society; vol. 77; (1955); p. 5892,5895, View in Reaxys
Phosphorescence Spectroscopy (1) Description References (Phosphores-
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
16/45
2016-06-01 13:02:51
cence Spectroscopy) Phosphorescence Aaron et al.; Clinica Chimica Acta; vol. 45; (1973); p. 375,379, View in Reaxys Other Spectroscopic Methods (1) Description (Oth- References er Spectroscopic Methods) Photoelectron spectrum
Domelsmith et al.; Journal of the American Chemical Society; vol. 99; (1977); p. 4311,4315, View in Reaxys; Domelsmith; Munchausen; Houk; Journal of Medicinal Chemistry; vol. 20; nb. 10; (1977); p. 1346 - 1348, View in Reaxys
Pharmacological Data (50) 1 of 50
Comment (Pharmacological Data)
Bioactivities present
Culvenor,C.C.J.; Ham,N.S.; Australian Journal of Chemistry; vol. 27; (1974); p. 2191 - 2198, View in Reaxys; Patent; Strahilevitz; Meir; US4620977; (1986); (A1) English, View in Reaxys; Patent; Merck Sharp and Dohme Limited; US5298520; (1994); (A1) English, View in Reaxys; Glennon; Liebowitz; Mack; Journal of Medicinal Chemistry; vol. 21; nb. 8; (1978); p. 822 - 825, View in Reaxys; Hall; McCapra; Scott; Tetrahedron; vol. 23; nb. 10; (1967); p. 4131 - 4141, View in Reaxys; Patent; Sanofi; US4977274; (1990); (A1) English, View in Reaxys; Julia,M. et al.; Bulletin de la Societe Chimique de France; (1973); p. 1424 - 1426, View in Reaxys; Fleming,I.; Woolias,M.; Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999); (1979); p. 829 837, View in Reaxys; Patent; Eli Lilly and Company; US5096908; (1992); (A1) English, View in Reaxys; Noell,C.W.; Cheng,C.C.; Journal of Heterocyclic Chemistry; vol. 3; (1966); p. 5 - 8, View in Reaxys; Patent; Wilburn, Michael D.; US2003/78231; (2003); (A1) English, View in Reaxys; Patent; Psychiatric Genomics, Inc.; US2003/82802; (2003); (A1) English, View in Reaxys; Hochstein; Paradies; Journal of the American Chemical Society; vol. 79; (1957); p. 5735, View in Reaxys; Vitali; Mossini; Bollettino Scientifico della Facolta di Chimica Industriale di Bologna; vol. 17; (1959); p. 84,86, View in Reaxys; Manske; Canadian Journal of Research; vol. 5; (1931); p. 599; Chem. Zentralbl.; vol. 103; nb. I; (1932); p. 2475, View in Reaxys; Hoshino; Shimodaira; Justus Liebigs Annalen der Chemie; vol. 520; (1935); p. 19,26, View in Reaxys; Fish et al.; Journal of the American Chemical Society; vol. 78; (1956); p. 3668,3670, View in Reaxys; Kondo et al.; Ann. Rep. ITSUU; Labor Nr. 10 <1959> 1, 8; engl. Ausg. S. 33, 42, View in Reaxys; Pachter et al.; Journal of Organic Chemistry; vol. 24; (1959); p. 1285, View in Reaxys; Goto et al.; Yakugaku Zasshi; vol. 78; (1958); p. 464,466; Chem.Abstr.; (1958); p. 14082, View in Reaxys; Fish et al.; Journal of the American Chemical Society; vol. 77; (1955); p. 5892,5895, View in Reaxys; Cohen et al.; Journal of the American Chemical Society; vol. 82; (1960); p. 2184, View in Reaxys; Brucato et al.; Arzneimittel Forschung; vol. 27; (1977); p. 1015,1017, View in Reaxys; Noell et al.; Journal of Heterocyclic Chemistry; vol. 3; (1966); p. 5,9, View in Reaxys; Siehr; Journal of the American Chemical Society; vol. 83; (1961); p. 2401, View in Reaxys; Bowd et al.; Photochemistry and Photobiology; vol. 11; (1970); p. 445,447, View in Reaxys; Bridges; Williams; Biochemical Journal; vol. 107; (1968); p. 225,228, View in Reaxys; Heinzelman; Szmuszkovicz; Progress in Drug Research; vol. 6; (1963); p. 75,76-150; Chem.Abstr.; vol. 60; nb. 13215b; (1964), View in Reaxys; Ganellin et al.; Journal of the Chemical Society [Section] C: Organic; (1967); p. 2220, View in Reaxys; Noland; Sundberg; Journal of Organic Chemistry; vol. 28; (1963); p. 884, View in Reaxys; Morimoto et al.; Justus Liebigs Annalen der Chemie; vol. 682; (1965); p. 212,218, View in Reaxys; Dutta; Ghosal; Chemistry and Industry (London, United Kingdom); (1967); p. 2046, View in Reaxys; Ghosal et al.; Phytochemistry (Elsevier); vol. 10; (1971); p. 2852, View in Reaxys; Ghosal et al.; Planta Medica; vol. 21; (1972); p. 398,401, View in Reaxys; Ghosal et al.; Planta Medica; vol. 21; (1972); p. 22,23, View in Reaxys; Julia et al.; Bulletin de la Societe Chimique de France; (1973); p. 1424, View in Reaxys; Agurell et al.; Acta Chemica Scandinavica (1947-1973); vol. 23; (1969); p. 903, View in Reaxys; Jackson; Smith; Journal of the Chemical Society; (1964); p. 5510,5511, View in Reaxys; Gasco; Farmaco, Edizione Scientifica; vol. 30; (1975); p. 512,513, View in Reaxys; Domelsmith et al.; Journal of the American Chemical Society; vol. 99; (1977); p. 4311,4315, View in Reaxys; Hall et al.; Tetrahedron; vol. 23; (1967); p. 4131, View in Reaxys; Arthur et al.; Australian Journal of Chemistry; vol. 20; (1967); p. 811,812, View in Reaxys; Bodendorf; Walk; Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft; vol. 294; (1961); p. 484,487, View in Reaxys; Raeisaenen; Kaerkkaeinen; Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry; vol. 33; (1979); p. 11, View in Reaxys; Pecher et al.; Tetrahedron Letters; (1961); p. 270,272, View in Reaxys; Ghosal; Bhattacharya; Planta Medica; vol. 22; (1972); p. 434,437, View in Reaxys; Ghosal; Singh; Bhattacharya; Planta medica; vol. 19; nb. 3; (1971); p. 280 - 284, View in Reaxys; Wenkert; Kryger; Journal of the Indian Chemical Society; vol. 55; (1978); p. 1122, View in Reaxys; Glennon; Gessner; Journal of Medicinal Chemistry; vol. 22; (1979); p. 428,430, View in Reaxys; Morimoto; Matsumoto; Justus Liebigs Annalen der Chemie; vol. 692; (1966); p. 194,197, View in Reaxys; Bergin et al.; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 24; (1968); p. 882, View in Reaxys; Poissan; Annales Pharmaceutiques Francaises; vol. 23; (1965); p. 241, View in Reaxys; Ghosal; Dutta; Sanyal; Bhattacharya; Journal of medicinal chemistry; vol. 12; nb. 3; (1969); p. 480 - 483, View in Reaxys; Julia; Ricalens; Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques; vol. 269; (1969); p. 51, View in Reaxys; Fitzgerald; Sioumis; Australian Journal of Chemistry; vol. 18; (1965); p. 433,434, View in Reaxys; Rovelli; Vaughan; Australian Journal of Chemistry; vol. 20; (1967); p. 1299, View in Reaxys; Kan-Fan et al.; Phytochemistry (Elsevier); vol. 9; (1970); p. 1283,1289, View in Reaxys; Domelsmith; Munchausen; Houk; Journal of Medicinal Chemistry; vol. 20; nb. 10; (1977); p. 1346 - 1348, View in Reaxys; Ghosal; Mazumder; Phytochemistry (Elsevier); vol. 10; (1971); p. 2840, View in Reaxys; Ghosal et al.; Journal of Pharmaceutical Sciences; vol. 60; (1971); p. 1209,1211, View in Reaxys; Ghosal; Mukherjee; Chemistry and Industry (London, United Kingdom);
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
17/45
2016-06-01 13:02:51
(1964); p. 1800, View in Reaxys; Tyler; Groeger; Planta Medica; vol. 12; (1964); p. 397,399, View in Reaxys; Falkenberg; Acta Crystallographica, Section B: Structural Crystallography and Crystal Chemistry; vol. 28; (1972); p. 3075, View in Reaxys; Marini-Bettolo et al.; Annali di Chimica (Rome, Italy); vol. 54; (1964); p. 1179,1185, View in Reaxys; Culvenor et al.; Australian Journal of Chemistry; vol. 17; (1964); p. 1301,1304, View in Reaxys; Banerjee; Ghosal; Australian Journal of Chemistry; vol. 22; (1969); p. 275, View in Reaxys; Ghosal; Banerjee; Australian Journal of Chemistry; vol. 22; (1969); p. 2029, View in Reaxys; Bellman; Journal - Association of Official Analytical Chemists; vol. 51; (1968); p. 164,169, View in Reaxys; Aaron et al.; Clinica Chimica Acta; vol. 45; (1973); p. 375,379, View in Reaxys; Corothie; Nakano; Planta Medica; vol. 17; (1969); p. 184,186, View in Reaxys; Ueno et al.; Chemical and Pharmaceutical Bulletin; vol. 26; (1978); p. 2411,2415, View in Reaxys; Ghosal; Planta Medica; vol. 21; (1972); p. 200,203, View in Reaxys; Kwatra; Simon; Salvador; Cooper; Journal of Medicinal Chemistry; vol. 21; nb. 3; (1978); p. 253 - 257, View in Reaxys; Chu; Wander; Tackett; et al.; Journal of Heterocyclic Chemistry; vol. 21; nb. 6; (1984); p. 1901 - 1903, View in Reaxys; Djura; Stierle; Sullivan; et al.; Journal of Organic Chemistry; vol. 45; nb. 8; (1980); p. 1435 - 1441, View in Reaxys; Tymiak; Rinehart Jr.; Bakus; Tetrahedron; vol. 41; nb. 6; (1985); p. 1039 - 1047, View in Reaxys; Kutney; Aweryn; Choi; et al.; Tetrahedron; vol. 39; nb. 22; (1983); p. 3781 - 3795, View in Reaxys; Grina, Jonas A.; Ratcliff, Matthew R.; Stermitz, Frank R.; Journal of Organic Chemistry; vol. 47; nb. 13; (1982); p. 2648 - 2651, View in Reaxys; Cain; Weber; Guzman; Cook; Barker; Rice; Crawley; Paul; Skolnick; Journal of Medicinal Chemistry; vol. 25; nb. 9; (1982); p. 1081 - 1091, View in Reaxys; Glennon; Jacyno; Young; McKenney; Nelson; Journal of Medicinal Chemistry; vol. 27; nb. 1; (1984); p. 41 - 45, View in Reaxys; Kline; Benington; Morin; Beaton; Glennon; Domelsmith; Houk; Rozeboom; Journal of Medicinal Chemistry; vol. 25; nb. 11; (1982); p. 1381 - 1383, View in Reaxys; Takechi, Haruko; Machida, Minoru; Kanaoka, Yuichi; Chemical & Pharmaceutical Bulletin; vol. 36; nb. 8; (1988); p. 2853 - 2863, View in Reaxys; Li, Liang; Lubman, David M.; Analytical Chemistry; vol. 60; nb. 23; (1988); p. 2591 - 2598, View in Reaxys; Kurz; Chatson; Constabel; et al.; Helvetica Chimica Acta; vol. 63; nb. 7; (1980); p. 1891 - 1896, View in Reaxys; Adron Harris; Homfeld; Campaigne; Journal of Pharmacy and Pharmacology; vol. 33; nb. 5; (1981); p. 320 - 322, View in Reaxys; Kawanishi, K.; Uhara, Y.; Hashimoto, Y.; Phytochemistry (Elsevier); vol. 24; nb. 6; (1985); p. 1373 - 1376, View in Reaxys; Mahboobi; Grothus; Meindl; Archiv der Pharmazie; vol. 327; nb. 2; (1994); p. 105 - 114, View in Reaxys; Chen; Senanayake; Bill; Larsen; Verhoeven; Reider; Journal of Organic Chemistry; vol. 59; nb. 13; (1994); p. 3738 - 3741, View in Reaxys; Kutney, James P.; Choi, Lewis S. L.; Kolodziejczyk, Pawel; Sleigh, Stephen K.; Stuart, Kenneth L.; et al.; Phytochemistry (Elsevier); vol. 19; (1980); p. 2589 - 2596, View in Reaxys; Tupitsyn, I. F.; Komarov, V. I.; J. Gen. Chem. USSR (Engl. Transl.); vol. 57; nb. 8; (1987); p. 1826 - 1835,1632 1640, View in Reaxys; Somei, Masanori; Kobayashi, Kensuke; Tanii, Keiko; Mochizuki, Toshihiko; Kawada, Yumiko; Fukui, Yoshikazu; Heterocycles; vol. 40; nb. 1; (1995); p. 119 - 122, View in Reaxys; Weniger; Rafik; Bastida; Quirion; Anton; Planta Medica; vol. 61; nb. 6; (1995); p. 569 - 570, View in Reaxys; Sintas, Jose A.; Vitale, Arturo A.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 39; nb. 8; (1997); p. 677 - 684, View in Reaxys; Yu; Ho; Liao; Chen; Journal of Natural Products; vol. 60; nb. 11; (1997); p. 1196 - 1198, View in Reaxys; Somei, Masanori; Yamada, Fumio; Morikawa, Harunobu; Heterocycles; vol. 46; (1997); p. 91 94, View in Reaxys; Carter; Champney; Hwang; Eglen; European Journal of Pharmacology; vol. 280; nb. 3; (1995); p. 243 - 250, View in Reaxys; Blair, Joseph B.; Marona-Lewicka, Danuta; Kanthasamy, Arthi; Lucaites, Virginia L.; Nelson, David L.; Nichols, David E.; Journal of Medicinal Chemistry; vol. 42; nb. 6; (1999); p. 1106 1111, View in Reaxys; Haefelinger, Guenter; Nimtz, Manfred; Horstmann, Volker; Benz, Thomas; Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences; vol. 54; nb. 3; (1999); p. 397 - 414, View in Reaxys; Leysen; Gommeren; Heylen; Luyten; Van De Weyer; Vanhoenacker; Haegeman; Schotte; Van Gompel; Wouters; Lesage; Molecular Pharmacology; vol. 50; nb. 6; (1996); p. 1567 - 1580, View in Reaxys; Lee, Tzong-Huei; Chou, Chang-Hung; Journal of the Chinese Chemical Society; vol. 47; nb. 6; (2000); p. 1287 - 1290, View in Reaxys; Somei; Yamada; Kurauchi; Nagahama; Hasegawa; Teranishi; Sato; Kaneko; Chemical and Pharmaceutical Bulletin; vol. 49; nb. 1; (2001); p. 87 - 96, View in Reaxys; Russell; Baker; Barden; Beer; Bristow; Broughton; Knowles; McAllister; Patel; Castro; Journal of Medicinal Chemistry; vol. 44; nb. 23; (2001); p. 3881 3895, View in Reaxys; Glennon, Richard A.; Bondarev, Mikhail; Roth, Bryan; Medicinal Chemistry Research; vol. 9; nb. 2; (1999); p. 108 - 117, View in Reaxys; Hong; Dukat; Teitler; Egan; Dupre; Herrick-Davis; Glennon; Medicinal Chemistry Research; vol. 9; nb. 6; (1999); p. 374 - 388, View in Reaxys; Barluenga, Jose; Fananas, Francisco J.; Sanz, Roberto; Fernandez, Yolanda; Chemistry - A European Journal; vol. 8; nb. 9; (2002); p. 2034 2046, View in Reaxys; Perez-Serrano, Leticia; Casarrubios, Luis; Dominguez, Gema; Freire, Guillermo; PerezCastells, Javier; Tetrahedron; vol. 58; nb. 27; (2002); p. 5407 - 5415, View in Reaxys; Wu, Tom Y. H.; Schulte, Peter G.; Organic Letters; vol. 4; nb. 23; (2002); p. 4033 - 4035, View in Reaxys; Altamura, Maria; Canfarini, Franca; Catalioto, Rose-Marie; Guidi, Antonio; Pasqui, Franco; Renzetti, Anna R.; Triolo, Antonio; Maggi, Carlo A.; Bioorganic and Medicinal Chemistry Letters; vol. 12; nb. 20; (2002); p. 2945 - 2948, View in Reaxys; Ebersole, Barbara J.; Visiers, Irache; Weinstein, Harel; Sealfon, Stuart C.; Molecular Pharmacology; vol. 63; nb. 1; (2003); p. 36 - 43, View in Reaxys; Pullagurla, Manik R.; Dukat, Malgorzata; Setola, Vincent; Roth, Bryan; Glennon, Richard A.; Bioorganic and Medicinal Chemistry Letters; vol. 13; nb. 19; (2003); p. 3355 - 3359, View in Reaxys; Dukat, Malgorzata; Smith, Carol; Herrick-Davis, Katharine; Teitler, Milt; Glennon, Richard A.; Bioorganic and Medicinal Chemistry; vol. 12; nb. 10; (2004); p. 2545 - 2552, View in Reaxys; Schmidt, Axel M.; Eilbracht, Peter; Journal of Organic Chemistry; vol. 70; nb. 14; (2005); p. 5528 - 5535, View in Reaxys; Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J.; Journal of Pharmacology and Experimental Therapeutics; vol. 306; nb. 1; (2003); p. 73 - 83, View in Reaxys; Qu, Shi-Jin; Liu, Quan-Wen; Tan, ChangHeng; Jiang, Shan-Hao; Zhu, Da-Yuan; Planta Medica; vol. 72; nb. 3; (2006); p. 264 - 266, View in Reaxys; Bunzow; Sonders; Arttamangkul; Harrison; Zhang; Quigley; Darland; Suchland; Pasumamula; Kennedy; Olson; Magenis; Amara; Grandy; Molecular Pharmacology; vol. 60; nb. 6; (2001); p. 1181 - 1188, View in Reaxys; Kolanos, Renata; Dukat, Malgorzata; Roth, Bryan L.; Glennon, Richard A.; Bioorganic and Medicinal Chemistry Letters; vol. 16; nb. 22; (2006); p. 5832 - 5835, View in Reaxys; Kristiansen, Kurt; Kroeze, Wesley K.; Willins, David L.; Gelber, Edward I.; Savage, Jason E.; Glennon, Richard A.; Roth, Bryan L.; Journal of Pharmacology and Ex-
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
18/45
2016-06-01 13:02:51
perimental Therapeutics; vol. 293; nb. 3; (2000); p. 735 - 736, View in Reaxys; Nyandege, Abner; Kolanos, Renata; Roth, Bryan L.; Glennon, Richard A.; Bioorganic and Medicinal Chemistry Letters; vol. 17; nb. 6; (2007); p. 1691 - 1694, View in Reaxys; Whitneys, Simon; Grigg, Ronald; Derrick, Andrew; Keep, Ann; Organic Letters; vol. 9; nb. 17; (2007); p. 3299 - 3302, View in Reaxys; Buchanan, Malcolm S.; Carroll, Anthony R.; Pass, David; Quinn, Ronald J.; Magnetic Resonance in Chemistry; vol. 45; nb. 4; (2007); p. 359 - 361, View in Reaxys; Patent; SUVEN PHARMACEUTICALS LTD.; WO2004/845; (2003); (A1) English, View in Reaxys; Patent; Suven Pharmaceuticals Ltd.; WO2004/205; (2003); (A2) English, View in Reaxys; Patent; Wilburn, Michael D.; US2003/7961; (2003); (A1) English, View in Reaxys; Dukat, Malgorzata; Mosier, Philip D.; Kolanos, Renata; Roth, Bryan L.; Glennon, Richard A.; Journal of Medicinal Chemistry; vol. 51; nb. 3; (2008); p. 603 - 611, View in Reaxys; Parker, Matthew A.; Kurrasch, Deborah M.; Nichols, David E.; Bioorganic and Medicinal Chemistry; vol. 16; nb. 8; (2008); p. 4661 - 4669, View in Reaxys; Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys; Patent; SUVEN PHARMACEUTICALS LTD.; WO2004/849; (2003); (A2) English, View in Reaxys; Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys; Moura, Sidnei; Carvalho, Felipe Garcia; de Oliveira, Carolina Dizioli Rodrigues; Pinto, Ernani; Yonamine, Mauricio; Phytochemistry Letters; vol. 3; nb. 2; (2010); p. 79 - 83, View in Reaxys; Alias, Asmah; Hazni, Hazrina; Jaafar, Faridahanim Mohd; Awang, Khalijah; Ismail, Nor Hadiani; Molecules; vol. 15; nb. 7; (2010); p. 4583 4588, View in Reaxys; Seki, Takayuki; Fujiwara, Tomoya; Takeuchi, Yoshio; Journal of Fluorine Chemistry; vol. 132; nb. 3; (2011); p. 181 - 185, View in Reaxys; Rack, Elisabeth; Froehlich, Roland; Schepmann, Dirk; Wuensch, Bernhard; Bioorganic and Medicinal Chemistry; vol. 19; nb. 10; (2011); p. 3141 - 3151, View in Reaxys; Qu, Shi-Jin; Wang, Gui-Feng; Duan, Wen-Hu; Yao, Shan-Yan; Zuo, Jian-Ping; Tan, Chang-Heng; Zhu, DaYuan; Bioorganic and Medicinal Chemistry; vol. 19; nb. 10; (2011); p. 3120 - 3127, View in Reaxys; Patent; THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS; KOZIKOWSKI, Alan; KALIN, Jay, Hans; BUTLER, Kyle, Vincent; BERGMAN, Joel; HANCOCK, Wayne, W.; WO2012/106343; (2012); (A2) English, View in Reaxys; Nirogi, Ramakrishna V.S.; Kambhampati, Ramasastri; Kothmirkar, Prabhakar; Konda, Jagadishbabu; Bandyala, Thrinath Reddy; Gudla, Parandhama; Arepalli, Sobhanadri; Gangadasari, Narasimhareddy P.; Shinde, Anil K.; Deshpande, Amol D.; Dwarampudi, Adireddy; Chindhe, Anil K.; Dubey, Pramod Kumar; Journal of Enzyme Inhibition and Medicinal Chemistry; vol. 27; nb. 3; (2012); p. 443 - 450, View in Reaxys; Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 60; nb. 37; (2012); p. 9512 - 9518,7, View in Reaxys; Ghanbari; Rowland-Yeo; Bloomer; Clarke; Lennard; Tucker; Rostami-Hodjegan; Current Drug Metabolism; vol. 7; nb. 3; (2006); p. 315 - 334, View in Reaxys; Kolanos, Renata; Dukat, Malgorzata; Roth, Bryan L; Glennon, Richard A; Bioorganic and medicinal chemistry letters; vol. 16; nb. 22; (2006); p. 5832 - 5835, View in Reaxys; Bonn, Britta; Masimirembwa, Collen M.; Aristei, Yasmin; Zamora, Ismael; Drug Metabolism and Disposition; vol. 36; nb. 11; (2008); p. 2199 2210, View in Reaxys; Volk, Balazs; Nagy, Bence J.; Vas, Szilvia; Kostyalik, Diana; Simig, Gyula; Bagdy, Gyoergy; Current Topics in Medicinal Chemistry; vol. 10; nb. 5; (2010); p. 554 - 578, View in Reaxys; Klein, Michael T.; Dukat, Malgorzata; Glennon, Richard A.; Teitler, Milt; Journal of Pharmacology and Experimental Therapeutics; vol. 337; nb. 3; (2011); p. 860 - 867, View in Reaxys; Gatch, Michael B.; Forster, Michael J.; Janowsky, Aaron; Eshleman, Amy J.; Journal of Pharmacology and Experimental Therapeutics; vol. 338; nb. 1; (2011); p. 280 - 289, View in Reaxys; Megalizzi, Veronique; Le Mercier, Marie; Decaestecker, Christine; Medicinal Research Reviews; vol. 32; nb. 2; (2012); p. 410 - 427, View in Reaxys; Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 60; nb. 37; (2012); p. 9512 - 9518, View in Reaxys; Patent; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; OZPOLAT, Bulent; LOPEZ-BERESTEIN, Gabriel; DALBY, Kevin N.; JOSE, Jiney; WO2013/63492; (2013); (A1) English, View in Reaxys; Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Casale, Rosario; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 61; nb. 21; (2013); p. 5156 5162, View in Reaxys; Winter; Gessner; Godse; Journal of medicinal chemistry; vol. 10; nb. 5; (1967); p. 856 858, View in Reaxys; Daly; Creveling; Witkop; Journal of medicinal chemistry; vol. 9; nb. 3; (1966); p. 273 - 280, View in Reaxys; Kalir; Szara; Journal of medicinal chemistry; vol. 9; nb. 3; (1966); p. 341 - 344, View in Reaxys; Campaigne; Neiss; Pfeiffer; Beck; Journal of medicinal chemistry; vol. 11; nb. 5; (1968); p. 1049 - 1054, View in Reaxys; Bennett Jr; Snyder; Molecular Pharmacology; vol. 12; nb. 3; (1976); p. 373 - 389, View in Reaxys; Lovell; Freedman; Molecular Pharmacology; vol. 12; nb. 4; (1976); p. 620 - 630, View in Reaxys; Fozard; Mobarok Ali; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 301; nb. 3; (1978); p. 223 - 235, View in Reaxys; Niswender, Colleen M.; Copeland, Sara C.; Herrick-Davis, Katharine; Emeson, Ronald B.; Sanders-Bush, Elaine; Journal of Biological Chemistry; vol. 274; nb. 14; (1999); p. 9472 - 9478, View in Reaxys; Roth, Bryan L.; Choudhary; Khan; Uluer; Journal of Pharmacology and Experimental Therapeutics; vol. 280; nb. 2; (1997); p. 576 - 583, View in Reaxys; Glennon; Ismaiel; Chaurasia; Titeler; Drug Development Research; vol. 22; nb. 1; (1991); p. 25 36, View in Reaxys; Deliganis; Pierce; Peroutka; Biochemical Pharmacology; vol. 41; nb. 11; (1991); p. 1739 1744, View in Reaxys; McKenna; Repke; Lo; Peroutka; Neuropharmacology; vol. 29; nb. 3; (1990); p. 193 - 198, View in Reaxys; Martin; MacLennan; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 342; nb. 2; (1990); p. 111 - 119, View in Reaxys; Johnson; Mathis; Shulgin; Hoffman; Nichols; Pharmacology, biochemistry, and behavior; vol. 35; nb. 1; (1990); p. 211 - 217, View in Reaxys; McKenna; Peroutka; The Journal of neuroscience : the official journal of the Society for Neuroscience; vol. 9; nb. 10; (1989); p. 3482 - 3490, View in Reaxys; Taylor; Nikam; Weck; Martin; Nelson; Life Sciences; vol. 41; nb. 16; (1987); p. 1961 - 1969, View in Reaxys; Offord; Ordway; Frazer; The Journal of pharmacology and experimental therapeutics; vol. 244; nb. 1; (1988); p. 144 - 153, View in Reaxys; Heuring; Peroutka; The Journal of neuroscience : the official journal of the Society for Neuroscience; vol. 7; nb. 3; (1987); p. 894 - 903, View in Reaxys; Lyon; Davis; Titeler; Molecular pharmacology; vol. 31; nb. 2; (1987); p. 194 - 199, View in Reaxys; Sills; Wolfe; Frazer; Journal of Pharmacology and Experimental Therapeutics; vol. 231; nb. 3; (1984); p. 480 - 487, View in Reaxys; Cascio; Kellar; European journal of pharmacology;
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
19/45
2016-06-01 13:02:51
vol. 95; nb. 1-2; (1983); p. 31 - 39, View in Reaxys; Nelson; Weck; Taylor; Advances in biochemical psychopharmacology; vol. 37; (1983); p. 337 - 347, View in Reaxys; Glennon; Jacyno; Salley Jr.; Journal of Medicinal Chemistry; vol. 25; nb. 1; (1982); p. 68 - 70, View in Reaxys; Weiss; Drummond; Molecular Pharmacology; vol. 20; nb. 3; (1981); p. 592 - 597, View in Reaxys; Kellar; Cascio; European journal of pharmacology; vol. 78; nb. 4; (1982); p. 475 - 478, View in Reaxys; Glennon; Schubert; Jacyno; Rosecrans; Journal of Medicinal Chemistry; vol. 23; nb. 11; (1980); p. 1222 - 1226, View in Reaxys; Glennon; Gessner; Journal of Medicinal Chemistry; vol. 22; nb. 4; (1979); p. 428 - 432, View in Reaxys; Glennon; Gessner; Godse; Kline; Journal of Medicinal Chemistry; vol. 22; nb. 11; (1979); p. 1414 - 1416, View in Reaxys; Northup; Mansour; Molecular Pharmacology; vol. 14; nb. 5; (1978); p. 804 - 819, View in Reaxys; Baldessarini; Kula; Walton; European Journal of Pharmacology; vol. 56; nb. 1-2; (1979); p. 167 - 171, View in Reaxys; Horn; Journal of Neurochemistry; vol. 21; nb. 4; (1973); p. 883 - 888, View in Reaxys; Patent; McConnell; Bruce; Locher; Christopher P.; (10 pag.); US5874477; (1999), View in Reaxys; , View in Reaxys; , View in Reaxys; Shiming Peng; Xingyu Lin; Zongru Guo; Niu Huang; Current topics in medicinal chemistry; vol. 12; nb. 12; (2012); p. 1363 - 1375, View in Reaxys; CLAIRE BAXTER; M. SLAYTOR; Phytochemistry; vol. 11; nb. 9; (1972); p. 2763 - 2766, View in Reaxys; SATYA P. GUPTA; PRITHVI SINGH; MAHESH C. BINDAL; Chemical reviews; vol. 83; nb. 6; (1983); p. 633 - 649, View in Reaxys; Sagnes, Charlene; Fournet, Guy; Satala, Grzegorz; Bojarski, Andrzej J.; Joseph, Benoit; European Journal of Medicinal Chemistry; vol. 75; (2014); p. 159 - 168, View in Reaxys; Chu, Uyen B.; Vorperian, Sevahn K.; Satyshur, Kenneth; Eickstaedt, Kelsey; Cozzi, Nicholas V.; Mavlyutov, Timur; Hajipour, Abdol R.; Ruoho, Arnold E.; Biochemistry; vol. 53; nb. 18; (2014); p. 2956 - 2965, View in Reaxys; He, Yi; Li, Xiaolong; Li, Jue; Li, Xiaocen; Guo, Li; Hai, Li; Wu, Yong; Tetrahedron Letters; vol. 55; nb. 29; (2014); p. 3938 - 3941, View in Reaxys; Bartolucci, Silvia; Mari, Michele; Bedini, Annalida; Piersanti, Giovanni; Spadoni, Gilberto; Journal of Organic Chemistry; vol. 80; nb. 6; (2015); p. 3217 - 3222, View in Reaxys; Calvert, Matthew B.; Sperry, Jonathan; Chemical Communications; vol. 51; nb. 28; (2015); p. 6202 - 6205, View in Reaxys; Tong, Shuo; Xu, Zhengren; Mamboury, Mathias; Wang, Qian; Zhu, Jieping; Angewandte Chemie - International Edition; vol. 54; nb. 40; (2015); p. 11809 - 11812; Angew. Chem.; vol. 127; nb. 40; (2015); p. 11975 - 11978,4, View in Reaxys; Patent; UNIVERSITÉ LAVAL; GUERTIN, Pierre; WO2015/127558; (2015); (A1) English, View in Reaxys; Patent; Jaswant S. Gidda; John M. Schaus; US5576352; (A); (1996), View in Reaxys; Patent; Jaswant S. Gidda; John M. Schaus; US5594034; (A); (1997), View in Reaxys; Olsen, Elisabeth K.; Hansen, Espen; Moodie, Lindon W. K.; Isaksson, Johan; Sepi, Kristina; Cergolj, Marija; Svenson, Johan; Andersen, Jeanette H.; Organic and Biomolecular Chemistry; vol. 14; nb. 5; (2016); p. 1629 1640, View in Reaxys 2 of 50
Comment (Pharmacological Data)
physiological behaviour discussed
Olsen, Elisabeth K.; Hansen, Espen; Moodie, Lindon W. K.; Isaksson, Johan; Sepi, Kristina; Cergolj, Marija; Svenson, Johan; Andersen, Jeanette H.; Organic and Biomolecular Chemistry; vol. 14; nb. 5; (2016); p. 1629 1640, View in Reaxys 3 of 50
Comment (Pharmacological Data)
physiological behaviour discussed
Servillo, Luigi; Giovane, Alfonso; Balestrieri, Maria Luisa; Casale, Rosario; Cautela, Domenico; Castaldo, Domenico; Journal of Agricultural and Food Chemistry; vol. 61; nb. 21; (2013); p. 5156 - 5162, View in Reaxys 4 of 50
Effect (Pharmacological Data)
cytotoxic
Species or Test-System (Pharmacological Data)
HepG2.2.15 cells
Further Details (Pharmacological Data)
MTT assay; cytotoxic concentration (CC)
Type (Pharmacological Data)
CC50
Value of Type (Pharmacological Data)
> 100 μmol/l
Qu, Shi-Jin; Wang, Gui-Feng; Duan, Wen-Hu; Yao, Shan-Yan; Zuo, Jian-Ping; Tan, Chang-Heng; Zhu, DaYuan; Bioorganic and Medicinal Chemistry; vol. 19; nb. 10; (2011); p. 3120 - 3127, View in Reaxys 5 of 50
Effect (Pharmacological Data)
hepatitis B virus DNA replication; inhibition of
Species or Test-System (Pharmacological Data)
HepG2.2.15 cells
Further Details (Pharmacological Data)
inhibitory concentration (IC)
Type (Pharmacological Data)
IC50
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
20/45
2016-06-01 13:02:51
Value of Type (Pharmacological Data)
> 100 μmol/l
Qu, Shi-Jin; Wang, Gui-Feng; Duan, Wen-Hu; Yao, Shan-Yan; Zuo, Jian-Ping; Tan, Chang-Heng; Zhu, DaYuan; Bioorganic and Medicinal Chemistry; vol. 19; nb. 10; (2011); p. 3120 - 3127, View in Reaxys 6 of 50
Effect (Pharmacological Data)
sigma-1 receptor; binding to
Species or Test-System (Pharmacological Data)
liver membrane homogenate
Method (Pharmacological Data)
Competition assays against the sigma-1 receptor specific ligand, (+)- [3H] -pentazocine (10 nM) determined that the non-methylated trace amines tryptamine, phenethylamine, and tyramine bound the sigma-1 receptor poorly (Table 4), with Kd values of 431.55 μM, 97.4 μM, and >30000 μM, respectively. By contrast, the iV-methylated and iV,./V-dimethylated derivatives of these compounds bound sigma-1 receptors more tightly, with a clear increase in affinity as the ligands approached the sigma-1 receptor ligand pharmacophore (Figures 5a and 5b). With the exception of the iV-methylated tyramines, this trend did not apply to the sigma-2 receptor, which differs pharmacologically and functionally from the sigma-1 receptor (Table 4).Tryptamine, phenethylamine, and iV-methyltyramine, had the highest sigma-2 receptor affinities with Kd values of 4.91 μM, 7.31 μM, and 6.61 μM, respectively. In contrast to sigma-1 receptors, iV-methylation and ΛζiV-dimethylation of tryptamine and phenethylamine decreased sigma- 2 receptor affinity (Table 4).; Preparation of rat, guinea pig, and mouse liver membrane homogenates was performed as previously described (18, 31) with the exception that mouse livers were obtained from age-matched adult 129/SvEvBrd x C57BL6/J sigma- 1 receptor knock out (27) and wild- type mice.; Sigma Receptor Binding Assays. Competitive binding assays were performed as previously described (18) with the exception of testing new ligands shown in Table 4.
Type (Pharmacological Data)
KD
Value of Type (Pharmacological Data)
14.75 μmol/l
Location
Page/Page column 29-30; 34-35
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 7 of 50
Effect (Pharmacological Data)
sigma-2 receptor; binding to
Species or Test-System (Pharmacological Data)
liver membrane homogenate
Method (Pharmacological Data)
Competition assays against the sigma-1 receptor specific ligand, (+)- [3H] -pentazocine (10 nM) determined that the non-methylated trace amines tryptamine, phenethylamine, and tyramine bound the sigma-1 receptor poorly (Table 4), with Kd values of 431.55 μM, 97.4 μM, and >30000 μM, respectively. By contrast, the iV-methylated and iV,./V-dimethylated derivatives of these compounds bound sigma-1 receptors more tightly, with a clear increase in affinity as the ligands approached the sigma-1 receptor ligand pharmacophore (Figures 5a and 5b). With the exception of the iV-methylated tyramines, this trend did not apply to the sigma-2 receptor, which differs pharmacologically and functionally from the sigma-1 receptor (Table 4).Tryptamine, phenethylamine, and iV-methyltyramine, had the highest sigma-2 receptor affinities with Kd values of 4.91 μM, 7.31 μM, and 6.61 μM, respectively. In contrast to sigma-1 receptors, iV-methylation and ΛζiV-dimethylation of tryptamine and phenethylamine decreased sigma- 2 receptor affinity (Table 4).; Preparation of rat, guinea pig, and mouse liver membrane homogenates was performed as previously described (18, 31) with the exception that mouse livers were obtained from age-matched adult 129/SvEvBrd x C57BL6/J sigma- 1 receptor knock out (27) and wild- type mice.; Sigma Receptor Binding Assays. Competitive binding assays were performed as previously described (18) with the exception of testing new ligands shown in Table 4.
Type (Pharmacological Data)
KD
Value of Type (Pharmacological Data)
21.71 μmol/l
Location
Page/Page column 29-30; 34-35
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
21/45
2016-06-01 13:02:51
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 8 of 50
Effect (Pharmacological Data)
sigma-1 receptor photolabeling; inhibition of
Species or Test-System (Pharmacological Data)
liver membranes photolabelled with 3-[125I]iodo-4-azidococaine of rat
Method (Pharmacological Data)
The ability of tryptamine, iV-methyltryptamine, and DMT to block sigma receptor photolabeling in rat liver homogenates were tested by two radioactive photoaffinity labels, the sigma-1 receptor specific cocaine derivative 3-[125I]iodo-4-azidococaine ([125I]-IACoC) (17) (Figure 6a), and the sigma-1 and sigma-2 receptor fenpropimorph derivative l-N-(2',6'-dimethyl- morpholino)-3-(4-azido-3-[125I]iodo-phenyl) propane ([125I]IAF) (18) (Figure 6b). Both of these compounds have been used to identify the drug binding region of the sigma-1 receptor (18, 19). [125I]-IACoC (sigma-1 Kd = 0.126 nM(l 7)) photolabeling of the 26 kDa sigma-1 receptor (Figure 6a) was protected best by DMT, with 61percent protection by 50 μM DMT and almost 100percent protection by 100 μM DMT. On the other hand, tryptamine and iV-methyltryptamine protected minimally against sigma-1 receptor [125I]-IACoC photolabeling, even at these high concentrations (Figure 6a). Similarly, [125I]IAF photolabeling of the sigma-1 (Kd = 194 nM (18)) receptor showed that DMT was the most potent protector. Ten μM DMT protected 31percent, while 50 μM and 100 μM DMT protected 43percent and 69percent, respectively (Figure 6b). With the exception of iV-methyltryptamine, protection of [125I]IAF sigma-2 (Kd = 2780 nM(iS)) receptor photolabeling paralleled the sigma-2 binding data. Tryptamine afforded the greatest protection of sigma-2 receptor photolabeling, with values of 47percent, 78percent, and 79percent for 10, 50, and 100 μM, respectively (Figure 6b).; Radiochemistry. Radiosynthesis of 3-[125I]iodo-4-azidococaine ([125I]-IACoC) (17) and 1-N- (2',6'dimethyl-morpholino)-3-(4-azido-3-[125I]iodo-phenyl) propane ([125I]IAF) (18) was performed as described. Preparation of Rat/Guinea Pig/Mouse Liver membranes. Preparation of rat, guinea pig, and mouse liver membrane homogenates was performed as previously described (18, 31) with the exception that mouse livers were obtained from age-matched adult 129/SvEvBrd x C57BL6/J sigma- 1 receptor knock out (27) and wild- type mice.; Photoaffinity Labeling. Sigma- 1 and sigma-2 receptors were photolabeled with 3-[125I]iodo- 4-azidococaine ([125I]-IACoC) and l-N-(2',6'-dimethyl-morpholino)-3-(4-azido-3-[125I]iodo-phenyl) propane ([125I]IAF) as described (18) with the exception of the protecting ligands, tryptamine, N- methyltryptamine, and iV,./V-dimethyltryptamine (DMT).
Results
band intensity sigma-1 (percent) = 124, 39 and 0.02 at a concentration of 10, 50 and 100 μmol/l, respectively
Location
Page/Page column 30; 34-35; 7/12
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 9 of 50
Effect (Pharmacological Data)
sigma-1 receptor photolabeling; inhibition of
Species or Test-System (Pharmacological Data)
liver membranes photolabelled with 1-N-(2',6'-dimethyl-morpholino)-3-(4-azido-3-[125I]iodophenyl)propane of rat
Method (Pharmacological Data)
The ability of tryptamine, iV-methyltryptamine, and DMT to block sigma receptor photolabeling in rat liver homogenates were tested by two radioactive photoaffinity labels, the sigma-1 receptor specific cocaine derivative 3-[125I]iodo-4-azidococaine ([125I]-IACoC) (17) (Figure 6a), and the sigma-1 and sigma-2 receptor fenpropimorph derivative l-N-(2',6'-dimethyl- morpholino)-3-(4-azido-3-[125I]iodo-phenyl) propane ([125I]IAF) (18) (Figure 6b). Both of these compounds have been used to identify the drug binding region of the sigma-1 receptor (18, 19). [125I]-IACoC (sigma-1 Kd = 0.126 nM(l 7)) photolabeling of the 26 kDa sigma-1 receptor (Figure 6a) was protected best by DMT, with 61percent protection by 50 μM DMT and almost 100percent protection by 100 μM DMT. On the other hand, tryptamine and iV-methyltryptamine protected minimally against sigma-1 receptor [125I]-IACoC photolabeling, even at these high concentrations (Figure 6a). Similarly, [125I]IAF photolabeling of the sigma-1 (Kd = 194 nM (18)) receptor showed that DMT was the most potent protector. Ten μM DMT protected 31percent, while 50 μM and 100 μM DMT protected 43percent and 69percent, respectively (Figure 6b). With the exception of iV-methyltryptamine, protection of [125I]IAF sigma-2 (Kd = 2780 nM(iS)) receptor photolabeling paralleled the sigma-2 binding data. Tryptamine afforded the greatest protection of sigma-2 receptor photolabeling, with values of 47percent, 78percent, and 79percent for 10, 50, and 100 μM, respectively (Figure 6b).; Radiochemistry. Radiosynthesis of 3-[125I]iodo-4-azidococaine ([125I]-IACoC) (17) and 1-N- (2',6'dimethyl-morpholino)-3-(4-azido-3-[125I]iodo-phenyl) pro-
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
22/45
2016-06-01 13:02:51
pane ([125I]IAF) (18) was performed as described. Preparation of Rat/Guinea Pig/Mouse Liver membranes. Preparation of rat, guinea pig, and mouse liver membrane homogenates was performed as previously described (18, 31) with the exception that mouse livers were obtained from age-matched adult 129/SvEvBrd x C57BL6/J sigma- 1 receptor knock out (27) and wild- type mice.; Photoaffinity Labeling. Sigma- 1 and sigma-2 receptors were photolabeled with 3-[125I]iodo- 4-azidococaine ([125I]-IACoC) and l-N-(2',6'-dimethyl-morpholino)-3-(4-azido-3-[125I]iodo-phenyl) propane ([125I]IAF) as described (18) with the exception of the protecting ligands, tryptamine, N- methyltryptamine, and iV,./V-dimethyltryptamine (DMT). Results
band intensity sigma-1 (percent) = 69, 57 and 31 at a concentration of 10, 50 and 100 μmol/l, respectively
Location
Page/Page column 30; 34-35; 7/12
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 10 of 50
Effect (Pharmacological Data)
sigma-2 receptor photolabeling; inhibition of
Species or Test-System (Pharmacological Data)
liver membranes photolabelled with 1-N-(2',6'-dimethyl-morpholino)-3-(4-azido-3-[125I]iodophenyl)propane of rat
Method (Pharmacological Data)
The ability of tryptamine, iV-methyltryptamine, and DMT to block sigma receptor photolabeling in rat liver homogenates were tested by two radioactive photoaffinity labels, the sigma-1 receptor specific cocaine derivative 3-[125I]iodo-4-azidococaine ([125I]-IACoC) (17) (Figure 6a), and the sigma-1 and sigma-2 receptor fenpropimorph derivative l-N-(2',6'-dimethyl- morpholino)-3-(4-azido-3-[125I]iodo-phenyl) propane ([125I]IAF) (18) (Figure 6b). Both of these compounds have been used to identify the drug binding region of the sigma-1 receptor (18, 19). [125I]-IACoC (sigma-1 Kd = 0.126 nM(l 7)) photolabeling of the 26 kDa sigma-1 receptor (Figure 6a) was protected best by DMT, with 61percent protection by 50 μM DMT and almost 100percent protection by 100 μM DMT. On the other hand, tryptamine and iV-methyltryptamine protected minimally against sigma-1 receptor [125I]-IACoC photolabeling, even at these high concentrations (Figure 6a). Similarly, [125I]IAF photolabeling of the sigma-1 (Kd = 194 nM (18)) receptor showed that DMT was the most potent protector. Ten μM DMT protected 31percent, while 50 μM and 100 μM DMT protected 43percent and 69percent, respectively (Figure 6b). With the exception of iV-methyltryptamine, protection of [125I]IAF sigma-2 (Kd = 2780 nM(iS)) receptor photolabeling paralleled the sigma-2 binding data. Tryptamine afforded the greatest protection of sigma-2 receptor photolabeling, with values of 47percent, 78percent, and 79percent for 10, 50, and 100 μM, respectively (Figure 6b).; Radiochemistry. Radiosynthesis of 3-[125I]iodo-4-azidococaine ([125I]-IACoC) (17) and 1-N- (2',6'dimethyl-morpholino)-3-(4-azido-3-[125I]iodo-phenyl) propane ([125I]IAF) (18) was performed as described. Preparation of Rat/Guinea Pig/Mouse Liver membranes. Preparation of rat, guinea pig, and mouse liver membrane homogenates was performed as previously described (18, 31) with the exception that mouse livers were obtained from age-matched adult 129/SvEvBrd x C57BL6/J sigma- 1 receptor knock out (27) and wild- type mice.; Photoaffinity Labeling. Sigma- 1 and sigma-2 receptors were photolabeled with 3-[125I]iodo- 4-azidococaine ([125I]-IACoC) and l-N-(2',6'-dimethyl-morpholino)-3-(4-azido-3-[125I]iodo-phenyl) propane ([125I]IAF) as described (18) with the exception of the protecting ligands, tryptamine, N- methyltryptamine, and iV,./V-dimethyltryptamine (DMT).
Results
band intensity sigma-2 (percent) = 58, 29 and 18 at a concentration of 10, 50 and 100 μmol/l, respectively
Location
Page/Page column 30; 34-35; 7/12
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 11 of 50
Effect (Pharmacological Data)
sodium channel; inhibition of
Species or Test-System (Pharmacological Data)
HEK293 cells expressing human cardiac Na+ channel hNav1.5
Method (Pharmacological Data)
To evaluate the capacity of DMT to induce physiological responses by binding to sigma receptors, the action of DMT on voltage-activated Na+ current was examined. Patch clamp recordings from HEK293 cells stably expressing the human cardiac Na+ channel hNavl.5 revealed voltage activated Na+ currents (INa) in response to voltage steps from -80 mV to -10 mV (Figure 7b). Application of 100 μM DMT inhibited INa by 62 +/- 3percent (n = 3), which reversed upon DMT removal. With hNavl.5 transiently transfected into COS-7 cells,
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
23/45
2016-06-01 13:02:51
100 μM DMT inhibited INa by only 22 + 4percent (n = 3), but photolabeling has shown that these cells have much lower levels of endogenous sigma- 1 receptor compared to HEK293 cells (26) (Figure 7b).The difference between DMT inhibition of INa in HEK293 and COS-7 cells (Figure 7b, p Na inhibition on sigma- 1 receptors. Experiments in cardiac myocytes demonstrated the same DMT action in a native preparation (Figure 7c), and enabled further demonstration of sigma- 1 receptor dependence by using a sigma- 1 receptor knockout mouse (27). [%125I]IAF photolabeling of liver homogenates from wildtype (WT) and sigma- 1 receptor knockout (KO) mice indeed showed the absence of sigma- 1 receptor (26 kDa) in the KO samples (Figure 7a). In WT neonatal cardiac myocytes, 100 μM DMT reversibly inhibited INa by 29 +/- 3percent (n = 7), while INa was reduced by only 7 +/- 2percent (n = 7) in KO myocytes (Figure 7c, p 0C in 5percent CO&2/air atmosphere, and used for electrophysiological recordings within 3-5 days.Neonatal Myocyte Isolation and Culture. Neonatal mouse cardiac myocytes were enzymatically isolated and cultured on laminin-coated glass coverslips as previously described (33, 34) with minor changes (26).; Electrophysiology. lNa was recorded using whole-cell patch clamp at room temperature. All patch clamp solutions used as well as patch clamp methodology and instrumentation details are previously described (26) with the exception of testing lNa inhibition with 100 μM DMT.
Results
INa inhibition (percent) = 62 at a concentration of 100 μmol/l
Location
Page/Page column 31; 35
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 12 of 50
Effect (Pharmacological Data)
sodium channel; inhibition of
Species or Test-System (Pharmacological Data)
COS-7 cells expressing human cardiac Na+ channel hNav1.5
Method (Pharmacological Data)
To evaluate the capacity of DMT to induce physiological responses by binding to sigma receptors, the action of DMT on voltage-activated Na+ current was examined. Patch clamp recordings from HEK293 cells stably expressing the human cardiac Na+ channel hNavl.5 revealed voltage activated Na+ currents (INa) in response to voltage steps from -80 mV to -10 mV (Figure 7b). Application of 100 μM DMT inhibited INa by 62 +/- 3percent (n = 3), which reversed upon DMT removal. With hNavl.5 transiently transfected into COS-7 cells, 100 μM DMT inhibited INa by only 22 + 4percent (n = 3), but photolabeling has shown that these cells have much lower levels of endogenous sigma- 1 receptor compared to HEK293 cells (26) (Figure 7b).The difference between DMT inhibition of INa in HEK293 and COS-7 cells (Figure 7b, p Na inhibition on sigma- 1 receptors. Experiments in cardiac myocytes demonstrated the same DMT action in a native preparation (Figure 7c), and enabled further demonstration of sigma- 1 receptor dependence by using a sigma- 1 receptor knockout mouse (27). [%125I]IAF
photolabeling of liver homogenates from wildtype (WT) and sigma- 1 receptor knockout (KO) mice indeed showed the absence of sigma- 1 receptor (26 kDa) in the KO samples (Figure 7a). In WT neonatal cardiac myocytes, 100 μM DMT reversibly inhibited INa by 29 +/- 3percent (n = 7), while INa was reduced by only 7 +/- 2percent (n = 7) in KO myocytes (Figure 7c, p 0C in 5percent CO&2/air atmosphere, and used for electrophysiological recordings within 3-5 days.Neonatal Myocyte Isolation and Culture. Neonatal mouse cardiac myocytes were enzymatically isolated and cultured on laminin-coated glass coverslips as previously described (33, 34) with minor changes (26).; Electrophysiology. lNa was recorded using whole-cell patch clamp at room temperature. All patch clamp solutions used as well as patch clamp methodology and instrumentation details are previously described (26) with the exception of testing lNa inhibition with 100 μM DMT. Results
INa inhibition (percent) = 22 at a concentration of 100 μmol/l
Location
Page/Page column 31; 35
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 13 of 50
Effect (Pharmacological Data)
sodium channel; inhibition of
Species or Test-System (Pharmacological Data)
neonatal cardiac myocytes of mouse
Method (Pharmacological Data)
To evaluate the capacity of DMT to induce physiological responses by binding to sigma receptors, the action of DMT on voltage-activated Na+ current was examined. Patch clamp recordings from HEK293 cells stably expressing the human cardiac Na+ channel hNavl.5 revealed voltage activated Na+ currents (INa) in response to voltage steps from -80 mV to
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
24/45
2016-06-01 13:02:51
-10 mV (Figure 7b). Application of 100 μM DMT inhibited INa by 62 +/- 3percent (n = 3), which reversed upon DMT removal. With hNavl.5 transiently transfected into COS-7 cells, 100 μM DMT inhibited INa by only 22 + 4percent (n = 3), but photolabeling has shown that these cells have much lower levels of endogenous sigma- 1 receptor compared to HEK293 cells (26) (Figure 7b).The difference between DMT inhibition of INa in HEK293 and COS-7 cells (Figure 7b, p Na inhibition on sigma- 1 receptors. Experiments in cardiac myocytes demonstrated the same DMT action in a native preparation (Figure 7c), and enabled further demonstration of sigma- 1 receptor dependence by using a sigma- 1 receptor knockout mouse (27). [%125I]IAF photolabeling of liver homogenates from wildtype (WT) and sigma- 1 receptor knockout (KO) mice indeed showed the absence of sigma- 1 receptor (26 kDa) in the KO samples (Figure 7a). In WT neonatal cardiac myocytes, 100 μM DMT reversibly inhibited INa by 29 +/- 3percent (n = 7), while INa was reduced by only 7 +/- 2percent (n = 7) in KO myocytes (Figure 7c, p 0C in 5percent CO&2/air atmosphere, and used for electrophysiological recordings within 3-5 days.Neonatal Myocyte Isolation and Culture. Neonatal mouse cardiac myocytes were enzymatically isolated and cultured on laminin-coated glass coverslips as previously described (33, 34) with minor changes (26).; Electrophysiology. lNa was recorded using whole-cell patch clamp at room temperature. All patch clamp solutions used as well as patch clamp methodology and instrumentation details are previously described (26) with the exception of testing lNa inhibition with 100 μM DMT.
Results
INa inhibition (percent) = 29 at a concentration of 100 μmol/l
Location
Page/Page column 31; 35
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 14 of 50
Effect (Pharmacological Data)
sodium channel; inhibition of
Species or Test-System (Pharmacological Data)
sigma-1 receptor knockout (KO) mouse neonatal cardiac myocytes
Method (Pharmacological Data)
To evaluate the capacity of DMT to induce physiological responses by binding to sigma receptors, the action of DMT on voltage-activated Na+ current was examined. Patch clamp recordings from HEK293 cells stably expressing the human cardiac Na+ channel hNavl.5 revealed voltage activated Na+ currents (INa) in response to voltage steps from -80 mV to -10 mV (Figure 7b). Application of 100 μM DMT inhibited INa by 62 +/- 3percent (n = 3), which reversed upon DMT removal. With hNavl.5 transiently transfected into COS-7 cells, 100 μM DMT inhibited INa by only 22 + 4percent (n = 3), but photolabeling has shown that these cells have much lower levels of endogenous sigma- 1 receptor compared to HEK293 cells (26) (Figure 7b).The difference between DMT inhibition of INa in HEK293 and COS-7 cells (Figure 7b, p Na inhibition on sigma- 1 receptors. Experiments in cardiac myocytes demonstrated the same DMT action in a native preparation (Figure 7c), and enabled further demonstration of sigma- 1 receptor dependence by using a sigma- 1 receptor knockout mouse (27). [%125I]IAF photolabeling of liver homogenates from wildtype (WT) and sigma- 1 receptor knockout (KO) mice indeed showed the absence of sigma- 1 receptor (26 kDa) in the KO samples (Figure 7a). In WT neonatal cardiac myocytes, 100 μM DMT reversibly inhibited INa by 29 +/- 3percent (n = 7), while INa was reduced by only 7 +/- 2percent (n = 7) in KO myocytes (Figure 7c, p 0C in 5percent CO&2/air atmosphere, and used for electrophysiological recordings within 3-5 days.Neonatal Myocyte Isolation and Culture. Neonatal mouse cardiac myocytes were enzymatically isolated and cultured on laminin-coated glass coverslips as previously described (33, 34) with minor changes (26).; Electrophysiology. lNa was recorded using whole-cell patch clamp at room temperature. All patch clamp solutions used as well as patch clamp methodology and instrumentation details are previously described (26) with the exception of testing lNa inhibition with 100 μM DMT.
Results
INa inhibition (percent) = 7 at a concentration of 100 μmol/l
Location
Page/Page column 31; 35
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 15 of 50
Effect (Pharmacological Data)
hypermobility induction
Species or Test-System (Pharmacological Data)
mouse
Route of Application
intraperitoneal
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
25/45
2016-06-01 13:02:51
Method (Pharmacological Data)
Mouse Behavior. All mice were maintained on a normal light/dark cycle and handled in accordance with Animal Care and Use Guidelines of the University of Wisconsin, Madison.Hypermobility effects induced by DMT in age-matched adult 129/SvEvBrd xC57BL6/J wild type (WT) and sigma- 1 receptor knockout (KO) mice were measured in an open-field assay. Mice were first acclimatized to the experimental room for one hour. WT and KO mice were injected with the monoamine oxidase inhibitor, pargyline (75 mg/kg, i.p.) two hours prior to DMT or vehicle injection(2S). The mice were observed in the open-field box for an hour and then injected with DMT (2 mg/kg, i.p.) (2S) or vehicle, and observed for 30 minutes. Each condition represents 8 to 14 mice (n = 8-14). For methamphetamine studies, WT and KO mice (n = 6) were placed in the open-field and observed for one hour prior to methamphetamine (3mg/kg, i.p.) injection (35) and observation (1 hour). A computer program was used to quantitate movement and after each experiment, 70percent ethanol was used to remove odors from the open-field.
Results
distance traveled over 30 min post-injection (cm) = ~7000 at a dose of 2 mg/kg
Location
Page/Page column 35; 9/12
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 16 of 50
Effect (Pharmacological Data)
hypermobility induction
Species or Test-System (Pharmacological Data)
sigma-1 receptor knockout (KO) mouse
Route of Application
intraperitoneal
Method (Pharmacological Data)
Mouse Behavior. All mice were maintained on a normal light/dark cycle and handled in accordance with Animal Care and Use Guidelines of the University of Wisconsin, Madison.Hypermobility effects induced by DMT in age-matched adult 129/SvEvBrd xC57BL6/J wild type (WT) and sigma- 1 receptor knockout (KO) mice were measured in an open-field assay. Mice were first acclimatized to the experimental room for one hour. WT and KO mice were injected with the monoamine oxidase inhibitor, pargyline (75 mg/kg, i.p.) two hours prior to DMT or vehicle injection(2S). The mice were observed in the open-field box for an hour and then injected with DMT (2 mg/kg, i.p.) (2S) or vehicle, and observed for 30 minutes. Each condition represents 8 to 14 mice (n = 8-14). For methamphetamine studies, WT and KO mice (n = 6) were placed in the open-field and observed for one hour prior to methamphetamine (3mg/kg, i.p.) injection (35) and observation (1 hour). A computer program was used to quantitate movement and after each experiment, 70percent ethanol was used to remove odors from the open-field.
Results
distance traveled over 30 min post-injection (cm) = ~2000 at a dose of 2 mg/kg
Location
Page/Page column 35; 9/12
Patent; Wisconsin Alumni Research Foundation; RUOHO, Arnold E.; HAJIPOUR, Abdol R.; CHU, Uyen B.; FONTANILLA, Dominique A.; WO2010/59711; (2010); (A1) English, View in Reaxys 17 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
brain frontal cortex homogenate of Sprague-Dawley rat
Sex
male
Method (Pharmacological Data)
5-HT2A receptor binding assay; tissue homogenate, <3H>MDL 100,907 and title comp. incub. for 15 min at 37 deg C in a shaking water bath; vacuum filtration performed; radioactivity measured using liquid scintillation spectroscopy at 37percent efficiency
Further Details (Pharmacological Data)
non-specific binding was determined in the presence of cinanserin (10 μM); Ki: binding affinity
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
1636 nmol/l
Parker, Matthew A.; Kurrasch, Deborah M.; Nichols, David E.; Bioorganic and Medicinal Chemistry; vol. 16; nb. 8; (2008); p. 4661 - 4669, View in Reaxys 18 of 50
Effect (Pharmacological Data)
functional activity
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
26/45
2016-06-01 13:02:51
Species or Test-System (Pharmacological Data)
rat
Method (Pharmacological Data)
drug discrimination assay using rats trained to distinguish the 5-HT2A receptor agonist LSD from saline; rat behavior observed
Results
title comp. indirectly determined to be an agonist of 5-HT2A receptor
Parker, Matthew A.; Kurrasch, Deborah M.; Nichols, David E.; Bioorganic and Medicinal Chemistry; vol. 16; nb. 8; (2008); p. 4661 - 4669, View in Reaxys 19 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
2.8 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 20 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Ala173Cys mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
1.13 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 21 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Ala173Ser mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
0.95 μmol/l
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
27/45
2016-06-01 13:02:51
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 22 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Ala173Met mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
0.63 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 23 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Ala173Leu mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
0.82 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 24 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Ala173Asp mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
0.43 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 25 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Ala173Thr mutant
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
28/45
2016-06-01 13:02:51
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
1.25 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 26 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Asp98Glu mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
1.42 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 27 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Tyr176Phe mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
3.7 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 28 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Thr439Val mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
29/45
2016-06-01 13:02:51
Value of Type (Pharmacological Data)
1.74 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 29 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Ala169Ile mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
1.74 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 30 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Thr439Ser mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
1.81 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 31 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Thr439Ala mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
2.2 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 32 of 50
Effect (Pharmacological Data)
5-HT uptake; inhibition of
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
30/45
2016-06-01 13:02:51
Species or Test-System (Pharmacological Data)
HEK-293 MSR cells transfected with hSERT, Tyr175Phe mutant
Method (Pharmacological Data)
inhibition of <3H>-5-HT uptake assayed; cells preincubated with title comp. for 30 min in PBSCM pH 7.4; uptake initiated by addition of <3H>-5-HT (50-100 nM) and continued for 10 min; cells lysed, radiolabeled 5-HT quantified by scintillation counting
Further Details (Pharmacological Data)
hSERT: human serotonin transporter
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
1.47 μmol/l
Celik, Leyla; Sinning, Steffen; Severinsen, Kasper; Hansen, Carsten G.; Moller, Maria S.; Bols, Mikael; Wiborg, Ove; Schiott, Birgit; Journal of the American Chemical Society; vol. 130; nb. 12; (2008); p. 3853 - 3865, View in Reaxys 33 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
HEK cell membranes
Method (Pharmacological Data)
radioligand binding assay; in triplicate; assay tubes containing membranes, 2.5 nmol/l <3H>5-HT and varying concentrations of title comp. incubated for 20 min at 37 deg C; suspensions filtered and counted in liquid scintillation counter
Further Details (Pharmacological Data)
HEK cells stably expressing human 5-HT1E receptor; methiothepin (10 μmol/l) used to define nonspecific binding; 5-HT, serotonin
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
300 nmol/l
Dukat, Malgorzata; Smith, Carol; Herrick-Davis, Katharine; Teitler, Milt; Glennon, Richard A.; Bioorganic and Medicinal Chemistry; vol. 12; nb. 10; (2004); p. 2545 - 2552, View in Reaxys 34 of 50
Effect (Pharmacological Data)
agonist
Species or Test-System (Pharmacological Data)
HEK293 cells expressing rTAR1
Concentration (Pharmacological Data)
1 μmol/l
Method (Pharmacological Data)
cells incubated in KRH with 100 μmol/l 3-isobutyl-1-methylxanthine and title comp. for 1 h at 37 deg C; cAMP content measured using competitive binding of <3H>cAMP to a cAMPbinding protein
Further Details (Pharmacological Data)
HEK: human embryonic kidney; rTAR1: rat trace amine receptor 1; reference comp.: forskolin; KRH: Krebs-Ringer-HEPES buffer
Results
title comp. induced cAMP production acting as agonist (diagram)
Bunzow; Sonders; Arttamangkul; Harrison; Zhang; Quigley; Darland; Suchland; Pasumamula; Kennedy; Olson; Magenis; Amara; Grandy; Molecular Pharmacology; vol. 60; nb. 6; (2001); p. 1181 - 1188, View in Reaxys 35 of 50
Comment (Pharmacological Data)
in vivo receptor affinity measurements at the rat brain 5-HT1A receptor and the cloned human 5-HT2 receptor family
Blair, Joseph B.; Marona-Lewicka, Danuta; Kanthasamy, Arthi; Lucaites, Virginia L.; Nelson, David L.; Nichols, David E.; Journal of Medicinal Chemistry; vol. 42; nb. 6; (1999); p. 1106 - 1111, View in Reaxys 36 of 50
Comment (Pharmacological Data)
hallucinogen-like activity in the two-lever drug discrimination paradigm using LSD-trained rats (ED50 = 10.16 μmol/kg)
Blair, Joseph B.; Marona-Lewicka, Danuta; Kanthasamy, Arthi; Lucaites, Virginia L.; Nelson, David L.; Nichols, David E.; Journal of Medicinal Chemistry; vol. 42; nb. 6; (1999); p. 1106 - 1111, View in Reaxys 37 of 50
Effect (Pharmacological Data)
receptor; binding activity
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
31/45
2016-06-01 13:02:51
Species or Test-System (Pharmacological Data)
COS-7 cells
Kind of Dosing (Pharmacological Data)
as oxalate
Method (Pharmacological Data)
h5-HT6 radioligand binding assay; 5-HT6-cDNA transfected by DEAE-dextran technique, harvested (centrifugated/washed) cells suspended in Tris-Cl/MgCl2/EDTA buffer (pH 7.40), room temp., 90 min, 1 nmol/l <3H>LSD, 10 μmol/l clozapine, title comp.
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
30 nmol/l
Glennon, Richard A.; Bondarev, Mikhail; Roth, Bryan; Medicinal Chemistry Research; vol. 9; nb. 2; (1999); p. 108 - 117, View in Reaxys 38 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
rat 5-HT2A receptors expressed in NIH-3T3 cells
Method (Pharmacological Data)
radioligand binding assay used 0.4 nM <3H>ketanserin; 10 μM mianserin used to define nonspecific binding
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
660 nmol/l
Hong; Dukat; Teitler; Egan; Dupre; Herrick-Davis; Glennon; Medicinal Chemistry Research; vol. 9; nb. 6; (1999); p. 374 - 388, View in Reaxys 39 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
rat 5-HT2C receptors expressed in A-9 cells
Method (Pharmacological Data)
radioligand binding assay used 1 nM <3H>mesulergine; 10 μM mesulergine used to define nonspecific binding
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
1250 nmol/l
Hong; Dukat; Teitler; Egan; Dupre; Herrick-Davis; Glennon; Medicinal Chemistry Research; vol. 9; nb. 6; (1999); p. 374 - 388, View in Reaxys 40 of 50
Comment (Pharmacological Data)
binding affinity to 5-HT1A receptors
Yu; Ho; Liao; Chen; Journal of Natural Products; vol. 60; nb. 11; (1997); p. 1196 - 1198, View in Reaxys 41 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
h5-HT1Dβ L929sA cells
Method (Pharmacological Data)
radioligand assay; incubation at 37 deg C, for 30 min; radioactivity measured by scintillation; in presence of <3H>5-alniditan (2 nM)
Further Details (Pharmacological Data)
Ki = apparent equilibrium inhibition constant
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
350 nmol/l
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
32/45
2016-06-01 13:02:51
Leysen; Gommeren; Heylen; Luyten; Van De Weyer; Vanhoenacker; Haegeman; Schotte; Van Gompel; Wouters; Lesage; Molecular Pharmacology; vol. 50; nb. 6; (1996); p. 1567 - 1580, View in Reaxys 42 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
h5-HT1Dβ L929sA cells
Method (Pharmacological Data)
radioligand assay; incubation at 37 deg C, for 30 min; radioactivity measured by scintillation; in presence of <3H>5-HT (4 nM)
Further Details (Pharmacological Data)
Ki = apparent equilibrium inhibition constant
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
91 nmol/l
Leysen; Gommeren; Heylen; Luyten; Van De Weyer; Vanhoenacker; Haegeman; Schotte; Van Gompel; Wouters; Lesage; Molecular Pharmacology; vol. 50; nb. 6; (1996); p. 1567 - 1580, View in Reaxys 43 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
h5-HT1Dα C6 glioma cells
Method (Pharmacological Data)
radioligand assay; incubation at 37 deg C, for 30 min; radioactivity measured by scintillation; in presence of <3H>5-HT (4 nM)
Further Details (Pharmacological Data)
Ki = apparent equilibrium inhibition constant
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
53 nmol/l
Leysen; Gommeren; Heylen; Luyten; Van De Weyer; Vanhoenacker; Haegeman; Schotte; Van Gompel; Wouters; Lesage; Molecular Pharmacology; vol. 50; nb. 6; (1996); p. 1567 - 1580, View in Reaxys 44 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
h5-HT1Dα C6 glioma cells
Method (Pharmacological Data)
radioligand assay; incubation at 37 deg C, for 30 min; radioactivity measured by scintillation; in presence of <3H>alniditan (2 nM)
Further Details (Pharmacological Data)
Ki = apparent equilibrium inhibition constant
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
106 nmol/l
Leysen; Gommeren; Heylen; Luyten; Van De Weyer; Vanhoenacker; Haegeman; Schotte; Van Gompel; Wouters; Lesage; Molecular Pharmacology; vol. 50; nb. 6; (1996); p. 1567 - 1580, View in Reaxys 45 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
5-HT1D calf substantia nigra
Method (Pharmacological Data)
radioligand assay; incubation at 37 deg C, for 30 min; radioactivity measured by scintillation; in presence of <3H>alniditan (2 nM)
Further Details (Pharmacological Data)
Ki = apparent equilibrium inhibition constant
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
33/45
2016-06-01 13:02:51
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
298 nmol/l
Leysen; Gommeren; Heylen; Luyten; Van De Weyer; Vanhoenacker; Haegeman; Schotte; Van Gompel; Wouters; Lesage; Molecular Pharmacology; vol. 50; nb. 6; (1996); p. 1567 - 1580, View in Reaxys 46 of 50
Effect (Pharmacological Data)
receptor; binding activity
Species or Test-System (Pharmacological Data)
5-HT1D calf substantia nigra
Method (Pharmacological Data)
radioligand assay; incubation at 37 deg C, for 30 min; radioactivity measured by scintillation; in presence of <3H>5-HT (4 nM)
Further Details (Pharmacological Data)
Ki = apparent equilibrium inhibition constant
Type (Pharmacological Data)
Ki
Value of Type (Pharmacological Data)
80 nmol/l
Leysen; Gommeren; Heylen; Luyten; Van De Weyer; Vanhoenacker; Haegeman; Schotte; Van Gompel; Wouters; Lesage; Molecular Pharmacology; vol. 50; nb. 6; (1996); p. 1567 - 1580, View in Reaxys 47 of 50
Effect (Pharmacological Data)
muscle relaxant
Species or Test-System (Pharmacological Data)
Dunkin-Hartley guinea-pig ileum
Sex
male
Method (Pharmacological Data)
250-350 g pigs killed, ileal segments suspended in Krebs solution + (μM) cocaine 10, corticosterone 10, pargyline 5, indomethacin, atropine 1 at 37 deg C, pH 7.4; H: without/with desensitization by 60 min equilibr. with 3 μM 5-carboxamidotryptamine
Further Details (Pharmacological Data)
contractions induced by 1 μM histamine (H) or 30 nM substance P (SP) for 30 s, 5 min dose-cycle; when stable contractions, title comp. added 3 min before spasmogen; change in isometric tension recorded
Results
concentration-dependent relaxation for contraction by H: pEC50: 6.0, relaxation: 106 percent; desens.: pEC: 5.9, relaxation: 93 percent; contraction by SP: no effect
Carter; Champney; Hwang; Eglen; European Journal of Pharmacology; vol. 280; nb. 3; (1995); p. 243 - 250, View in Reaxys 48 of 50
Comment (Pharmacological Data)
activity against Mycobacterium tuberculosis H 37 Ra, MIC: 256 μg/ml
Mahboobi; Grothus; Meindl; Archiv der Pharmazie; vol. 327; nb. 2; (1994); p. 105 - 114, View in Reaxys 49 of 50
Comment (Pharmacological Data)
in vitro inhibition of <3H>diazepam binding to rat cerebral cortical membranes
Cain; Weber; Guzman; Cook; Barker; Rice; Crawley; Paul; Skolnick; Journal of Medicinal Chemistry; vol. 25; nb. 9; (1982); p. 1081 - 1091, View in Reaxys 50 of 50
Comment (Pharmacological Data)
hallucinogenic activity; ED 50: 15 μmol/kg (rats, intraperitoneally)
Adron Harris; Homfeld; Campaigne; Journal of Pharmacy and Pharmacology; vol. 33; nb. 5; (1981); p. 320 - 322, View in Reaxys Ecotoxicology (1) 1 of 1
Effect (Ecotoxicology)
phytotoxicity
Species or Test-System (Ecotoxicology)
Lactuca sativa, lettuce
Concentration (Ecotoxicology)
14 - 84 mmol/l
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
34/45
2016-06-01 13:02:51
Method (Ecotoxicology)
chromatographic bioassay method; 10 lettuce seeds planted on paper spotted with methanolic solution of title comp.; 26 deg C; incubation time 72 h; radicle growth of lettuce in mm was measured
Results
title comp. exerted significant phytotoxicity at conc. lower than 14 mmol/l; graphical representation
Lee, Tzong-Huei; Chou, Chang-Hung; Journal of the Chinese Chemical Society; vol. 47; nb. 6; (2000); p. 1287 1290, View in Reaxys Use (6) Use Pattern
Location
References
Parkinson's disease (PD)
Page/Page column 20-23
Patent; UNIVERSITÉ LAVAL; GUERTIN, Pierre; WO2015/127558; (2015); (A1) English, View in Reaxys
Pharmaceuticals
Page/Page column 20-23
Patent; UNIVERSITÉ LAVAL; GUERTIN, Pierre; WO2015/127558; (2015); (A1) English, View in Reaxys
inducing or facilitating micturition in combination with 5-HT1A receptor agonist, 5HT1A/7 receptor agonist, cholinesterase inhibitor, NMDA receptor agonist, noradrenaline/dopamine precursor
Page/Page column 20-23
Patent; UNIVERSITÉ LAVAL; GUERTIN, Pierre; WO2015/127558; (2015); (A1) English, View in Reaxys
multiple sclerosis (MS)
Page/Page column 20-23
Patent; UNIVERSITÉ LAVAL; GUERTIN, Pierre; WO2015/127558; (2015); (A1) English, View in Reaxys
spinal cord injury (SCI)
Page/Page column 20-23
Patent; UNIVERSITÉ LAVAL; GUERTIN, Pierre; WO2015/127558; (2015); (A1) English, View in Reaxys
urinary retention
Page/Page column 20-23
Patent; UNIVERSITÉ LAVAL; GUERTIN, Pierre; WO2015/127558; (2015); (A1) English, View in Reaxys
Isolation from Natural Product (41) Isolation from References Natural Product bark of Fissistigma latifolium (Dunal) Merr. (Annonaceae); collected from Dungun,Terengganu
Alias, Asmah; Hazni, Hazrina; Jaafar, Faridahanim Mohd; Awang, Khalijah; Ismail, Nor Hadiani; Molecules; vol. 15; nb. 7; (2010); p. 4583 - 4588, View in Reaxys
Acacia confusa
Buchanan, Malcolm S.; Carroll, Anthony R.; Pass, David; Quinn, Ronald J.; Magnetic Resonance in Chemistry; vol. 45; nb. 4; (2007); p. 359 - 361, View in Reaxys
Evodia fargesii Qu, Shi-Jin; Liu, Quan-Wen; Tan, Chang-Heng; Jiang, Shan-Hao; Zhu, Da-Yuan; Planta Medica; vol. 72; Dode (Rutaceae), nb. 3; (2006); p. 264 - 266, View in Reaxys roots and stems (Zhangshu, Jiangxi province, China) roots of Acacia confusa Merr. (Leguminosae), Nankang, Taipei, September 1999
Lee, Tzong-Huei; Chou, Chang-Hung; Journal of the Chinese Chemical Society; vol. 47; nb. 6; (2000); p. 1287 - 1290, View in Reaxys
the dried, unripe fruit of Evodia rutaecarpa
Yu; Ho; Liao; Chen; Journal of Natural Products; vol. 60; nb. 11; (1997); p. 1196 - 1198, View in Reaxys
Antirhea lucida (Sw.)
Weniger; Rafik; Bastida; Quirion; Anton; Planta Medica; vol. 61; nb. 6; (1995); p. 569 - 570, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
35/45
2016-06-01 13:02:51
bark of Virola sebifera Aublet
Kawanishi, K.; Uhara, Y.; Hashimoto, Y.; Phytochemistry (Elsevier); vol. 24; nb. 6; (1985); p. 1373 - 1376, View in Reaxys
Catharanthus roseus 953. cell line
Kutney; Aweryn; Choi; et al.; Tetrahedron; vol. 39; nb. 22; (1983); p. 3781 - 3795, View in Reaxys
leaves of ZanGrina, Jonas A.; Ratcliff, Matthew R.; Stermitz, Frank R.; Journal of Organic Chemistry; vol. 47; nb. 13; thoxylum arbores- (1982); p. 2648 - 2651, View in Reaxys cens batches of 953 line Catharanthus roseus cell cultures
Kurz; Chatson; Constabel; et al.; Helvetica Chimica Acta; vol. 63; nb. 7; (1980); p. 1891 - 1896, View in Reaxys
'943' cell line of Catharanthus roseus cell cultures
Kutney, James P.; Choi, Lewis S. L.; Kolodziejczyk, Pawel; Sleigh, Stephen K.; Stuart, Kenneth L.; et al.; Phytochemistry (Elsevier); vol. 19; (1980); p. 2589 - 2596, View in Reaxys
aus Wurzeln od. Stielen v. Desmodium candatum
Ueno et al.; Chemical and Pharmaceutical Bulletin; vol. 26; (1978); p. 2411,2415, View in Reaxys
Vork. u. Isol. aus Ghosal; Planta Medica; vol. 21; (1972); p. 200,203, View in Reaxys Banistereopsis argentea Vork. u. Isol. aus Phalaris arundinacea
Ghosal; Planta Medica; vol. 21; (1972); p. 200,203, View in Reaxys
Vork. u. Isol. aus Arundo donax
Ghosal et al.; Planta Medica; vol. 21; (1972); p. 22,23, View in Reaxys; Ghosal; Planta Medica; vol. 21; (1972); p. 200,203, View in Reaxys
Vork. u. Isol. aus Mucuna pruriens
Ghosal; Singh; Bhattacharya; Planta medica; vol. 19; nb. 3; (1971); p. 280 - 284, View in Reaxys; Ghosal; Planta Medica; vol. 21; (1972); p. 200,203, View in Reaxys
Vork. u. Isol. aus Desmodium gangeticum
Ghosal; Bhattacharya; Planta Medica; vol. 22; (1972); p. 434,437, View in Reaxys; Ghosal; Planta Medica; vol. 21; (1972); p. 200,203, View in Reaxys
Vork. u. Isol. aus Desmodium pulchellum
Ghosal et al.; Planta Medica; vol. 21; (1972); p. 398,401, View in Reaxys; Ghosal; Planta Medica; vol. 21; (1972); p. 200,203, View in Reaxys
aus Banistereopsis argentea
Ghosal; Mazumder; Phytochemistry (Elsevier); vol. 10; (1971); p. 2840, View in Reaxys; Ghosal et al.; Journal of Pharmaceutical Sciences; vol. 60; (1971); p. 1209,1211, View in Reaxys
aus Arundo donax
Ghosal et al.; Phytochemistry (Elsevier); vol. 10; (1971); p. 2852, View in Reaxys
aus Vepris ampody
Kan-Fan et al.; Phytochemistry (Elsevier); vol. 9; (1970); p. 1283,1289, View in Reaxys
Rinde von Virola sebifera
Corothie; Nakano; Planta Medica; vol. 17; (1969); p. 184,186, View in Reaxys
aus Anadenanthera peregrina
Agurell et al.; Acta Chemica Scandinavica (1947-1973); vol. 23; (1969); p. 903, View in Reaxys
aus 'Epena-Snuff'
Agurell et al.; Acta Chemica Scandinavica (1947-1973); vol. 23; (1969); p. 903, View in Reaxys
aus Virola Arten
Agurell et al.; Acta Chemica Scandinavica (1947-1973); vol. 23; (1969); p. 903, View in Reaxys
aus 'NyakwanaSnuff'
Agurell et al.; Acta Chemica Scandinavica (1947-1973); vol. 23; (1969); p. 903, View in Reaxys
aus Arundo donax L.
Dutta; Ghosal; Chemistry and Industry (London, United Kingdom); (1967); p. 2046, View in Reaxys; Ghosal; Dutta; Sanyal; Bhattacharya; Journal of medicinal chemistry; vol. 12; nb. 3; (1969); p. 480 - 483, View in Reaxys
aus Acacia phlebophylla
Rovelli; Vaughan; Australian Journal of Chemistry; vol. 20; (1967); p. 1299, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
36/45
2016-06-01 13:02:51
aus d. Stielen v. Acacia confusa Merr.
Arthur et al.; Australian Journal of Chemistry; vol. 20; (1967); p. 811,812, View in Reaxys
aus d. WurzelMorimoto; Matsumoto; Justus Liebigs Annalen der Chemie; vol. 692; (1966); p. 194,197, View in Reaxys rinde d. Extraktion m. Me. (Trennung d. Chromatographie) (S.198) aus d. Blaettern v. Morimoto; Matsumoto; Justus Liebigs Annalen der Chemie; vol. 692; (1966); p. 194,197, View in Reaxys Lespedeza bicolor var. japonica Nakai (Yamahagi) d. Extraktion m. Me. (Trennung d. Chromatographie) aus Acacia maidenii F. Muell.
Fitzgerald; Sioumis; Australian Journal of Chemistry; vol. 18; (1965); p. 433,434, View in Reaxys
aus d. Blaettern v. Poissan; Annales Pharmaceutiques Francaises; vol. 23; (1965); p. 241, View in Reaxys Natem- u. YageStraeuchern aus Desmodium Ghosal; Mukherjee; Chemistry and Industry (London, United Kingdom); (1964); p. 1800, View in Reaxys Pulchellum Benth. ex Baker aus Phalaris tuberosa
Culvenor et al.; Australian Journal of Chemistry; vol. 17; (1964); p. 1301,1304, View in Reaxys
Vork. u. Isol. aus Amanita citrina
Tyler; Groeger; Planta Medica; vol. 12; (1964); p. 397,399, View in Reaxys
Vork. u. Isol. aus Amanita porphyria
Tyler; Groeger; Planta Medica; vol. 12; (1964); p. 397,399, View in Reaxys
Vork. im 'Epena'Pulver (z.B. v. Mimosa acacioides od. Piptadeia peregrina)
Marini-Bettolo et al.; Annali di Chimica (Rome, Italy); vol. 54; (1964); p. 1179,1185, View in Reaxys
Isolierung aus den Wurzeln von Mimosa hostilis
Pachter et al.; Journal of Organic Chemistry; vol. 24; (1959); p. 1285, View in Reaxys
Isolierung aus den Blaettern von Lespedeza bicolor var. japonica
Goto et al.; Yakugaku Zasshi; vol. 78; (1958); p. 464,466; Chem.Abstr.; (1958); p. 14082, View in Reaxys
Isolierung aus den Blaettern von Prestonia amazonicum
Hochstein; Paradies; Journal of the American Chemical Society; vol. 79; (1957); p. 5735, View in Reaxys
Reaxys ID 3785982 View in Reaxys
2/12 CAS Registry Number: 4382-50-7 Chemical Name: N,N-Dimethyltryptamine oxalate; (2-indol-3yl-ethyl)-dimethyl-amine; oxalate; (2-Indol-3-yl-aethyl)-dimethylamin; Oxalat Linear Structure Formula: C12H16N2*C2H2O4 Molecular Formula: C2H2O4*C12H16N2 Molecular Weight: 278.308 Type of Substance: heterocyclic InChI Key: LWHZUMHODQLJKN-UHFFFAOYSA-N
N HO O
O OH
NH
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
37/45
2016-06-01 13:02:51
Note: Melting Point (2) 1 of 2
Melting Point [°C]
151
Sintas, Jose A.; Vitale, Arturo A.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 39; nb. 8; (1997); p. 677 - 684, View in Reaxys 2 of 2
Melting Point [°C]
151 - 152
Solvent (Melting Point)
methanol
Kondo et al.; Ann. Rep. ITSUU; Labor Nr. 10 <1959> 1, 8; engl. Ausg. S. 33, 42, View in Reaxys Pharmacological Data (1) 1 of 1
Comment (Pharmacological Data)
Bioactivities present
Glennon; Liebowitz; Mack; Journal of Medicinal Chemistry; vol. 21; nb. 8; (1978); p. 822 - 825, View in Reaxys; Kondo et al.; Ann. Rep. ITSUU; Labor Nr. 10 <1959> 1, 8; engl. Ausg. S. 33, 42, View in Reaxys; Sintas, Jose A.; Vitale, Arturo A.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 39; nb. 8; (1997); p. 677 - 684, View in Reaxys; Glennon, Richard A.; Dukat, Malgorzata; Grella, Brian; Hong, Seoung-Soo; Costantino, Luca; Teitler, Milt; Smith, Carol; Egan, Chris; Davis, Katherine; Mattson, Mariena V.; Drug and Alcohol Dependence; vol. 60; nb. 2; (2000); p. 121 - 132, View in Reaxys; Teitler, Milt; Scheick, Cynthia; Howard, Paul; Sullivan III, Joseph E.; Iwamura, Tatsunori; Glennon, Richard A.; Medicinal Chemistry Research; vol. 7; nb. 4; (1997); p. 207 - 218, View in Reaxys; Becker; Gettys; Middleton; Olsen; Albers; Lee -; Fanburg; Raymond; Molecular Pharmacology; vol. 42; nb. 5; (1992); p. 817 - 825, View in Reaxys; Lyon; Titeler; Seggel; Glennon; European Journal of Pharmacology; vol. 145; nb. 3; (1988); p. 291 - 297, View in Reaxys; Glennon; Young; Rosecrans; Kallman; Psychopharmacology; vol. 68; nb. 2; (1980); p. 155 - 158, View in Reaxys; Glennon; Gessner; Journal of Medicinal Chemistry; vol. 22; nb. 4; (1979); p. 428 - 432, View in Reaxys; Ross; Renyi; European journal of pharmacology; vol. 7; nb. 3; (1969); p. 270 - 277, View in Reaxys
Reaxys ID 3705170 View in Reaxys
3/12 CAS Registry Number: 2826-93-9 Chemical Name: N,N-dimethyltryptamine hydrochloride; (2-indol-3-yl-ethyl)-dimethyl-amine; hydrochloride; (2-Indol-3-yl-aethyl)-dimethyl-amin; Hydrochlorid Linear Structure Formula: C12H16N2*ClH Molecular Formula: C12H16N2*ClH Molecular Weight: 224.733 Type of Substance: heterocyclic InChI Key: FXCHKLOHTIIVJW-UHFFFAOYSA-N Note:
N Cl
H
NH
Melting Point (1) 1 of 1
Melting Point [°C]
166 - 167.5
Solvent (Melting Point)
ethanol; diethyl ether
Vitali; Mossini; Bollettino Scientifico della Facolta di Chimica Industriale di Bologna; vol. 17; (1959); p. 84,86, View in Reaxys
Reaxys ID 3794124 View in Reaxys
4/12
N
CAS Registry Number: 68677-26-9 Chemical Name: N,N-dimethyltryptamine fumarate; (2-indol-3yl-ethyl)-dimethyl-amine; fumarate; (2-Indol-3-yl-aethyl)-dimethyl-amin; Fumarat Linear Structure Formula: C12H16N2*C4H4O4 Molecular Formula: C4H4O4*C12H16N2 Molecular Weight: 304.346 Type of Substance: heterocyclic InChI Key: OHMVTPSXVQQKPA-WLHGVMLRSA-N Note:
O HO
E
OH
O NH
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
38/45
2016-06-01 13:02:51
Melting Point (1) 1 of 1
Melting Point [°C]
152 - 152.5
Solvent (Melting Point)
ethanol; butan-2-one; diethyl ether
Barlow; Khan; British Journal of Pharmacology and Chemotherapy; vol. 14; (1958); p. 99,100, View in Reaxys Pharmacological Data (2) 1 of 2
Comment (Pharmacological Data)
Bioactivities present
Barlow; Khan; British Journal of Pharmacology and Chemotherapy; vol. 14; (1958); p. 99,100, View in Reaxys; Eshleman, Amy J.; Forster, Michael J.; Wolfrum, Katherine M.; Johnson, Robert A.; Janowsky, Aaron; Gatch, Michael B.; Psychopharmacology; vol. 231; nb. 5; (2014); p. 875 - 888, View in Reaxys 2 of 2
Comment (Pharmacological Data)
physiological behaviour discussed
Eshleman, Amy J.; Forster, Michael J.; Wolfrum, Katherine M.; Johnson, Robert A.; Janowsky, Aaron; Gatch, Michael B.; Psychopharmacology; vol. 231; nb. 5; (2014); p. 875 - 888, View in Reaxys
Reaxys ID 3863056 View in Reaxys
5/12 CAS Registry Number: 1667-91-0 Chemical Name: (2-indol-3-yl-ethyl)-dimethyl-amine; picrate; (2-Indol-3-yl-aethyl)-dimethyl-amin; Picrat Linear Structure Formula: C12H16N2*C6H3N3O7 Molecular Formula: C6H3N3O7*C12H16N2 Molecular Weight: 417.378 Type of Substance: heterocyclic InChI Key: RWEYDVPLQNZXNK-UHFFFAOYSA-N Note:
O O
N
N O
HO
N O
O
NH
N O
Melting Point (2) 1 of 2
Melting Point [°C]
171 - 172
Solvent (Melting Point)
benzene
Pachter et al.; Journal of Organic Chemistry; vol. 24; (1959); p. 1285, View in Reaxys 2 of 2
Melting Point [°C]
170 - 171
Solvent (Melting Point)
methanol
Hoshino; Shimodaira; Justus Liebigs Annalen der Chemie; vol. 520; (1935); p. 19,26, View in Reaxys Crystal Property Description (1) Colour & Other References Properties gelb
Pachter et al.; Journal of Organic Chemistry; vol. 24; (1959); p. 1285, View in Reaxys
Reaxys ID 11196838 View in Reaxys
2
H
2
H
2H
6/12 Chemical Name: N,N-dimethyl-[α,α,β,β-d4]-tryptamine; 3-(2-dimethylamino-[2H4]-ethyl)-1H-indole Linear Structure Formula: C12H12 (2)H4N2 Molecular Formula: C12H16N2 Molecular Weight: 192.241 InChI Key: DMULVCHRPCFFGV-OSEHSPPNSA-N Note:
N 2H
NH
Substance Label (1) Label References 8
Wang, Yu-Yun; Chen, Chinpiao; Journal of the Chinese Chemical Society; vol. 54; nb. 5; (2007); p. 1363 1368, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
39/45
2016-06-01 13:02:51
Melting Point (1) 1 of 1
Melting Point [°C]
43 - 44
Wang, Yu-Yun; Chen, Chinpiao; Journal of the Chinese Chemical Society; vol. 54; nb. 5; (2007); p. 1363 - 1368, View in Reaxys NMR Spectroscopy (4) 1 of 4
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
300.1
Brandt, Simon D.; Tirunarayanapuram, Sri Subha; Freeman, Sally; Dempster, Nicola; Barker, Steven A.; Daley, Paul F.; Cozzi, Nicholas V.; Martins, Claudia P. B.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 51; nb. 14; (2008); p. 423 - 429, View in Reaxys 2 of 4
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- chloroform-d1 scopy) Frequency (NMR Spectroscopy) [MHz]
75.5
Brandt, Simon D.; Tirunarayanapuram, Sri Subha; Freeman, Sally; Dempster, Nicola; Barker, Steven A.; Daley, Paul F.; Cozzi, Nicholas V.; Martins, Claudia P. B.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 51; nb. 14; (2008); p. 423 - 429, View in Reaxys 3 of 4
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]
100.6
Wang, Yu-Yun; Chen, Chinpiao; Journal of the Chinese Chemical Society; vol. 54; nb. 5; (2007); p. 1363 - 1368, View in Reaxys 4 of 4
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]
300
Wang, Yu-Yun; Chen, Chinpiao; Journal of the Chinese Chemical Society; vol. 54; nb. 5; (2007); p. 1363 - 1368, View in Reaxys IR Spectroscopy (1) 1 of 1
Description (IR Spectroscopy)
Bands
Solvent (IR Spectroscopy)
film
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
40/45
2016-06-01 13:02:51
Wang, Yu-Yun; Chen, Chinpiao; Journal of the Chinese Chemical Society; vol. 54; nb. 5; (2007); p. 1363 - 1368, View in Reaxys Mass Spectrometry (2) Description (Mass Comment (Mass Spectrometry) Spectrometry)
References
ESI (Electrospray mol peak ionisation); HRMS (High resolution mass spectrometry)
Brandt, Simon D.; Tirunarayanapuram, Sri Subha; Freeman, Sally; Dempster, Nicola; Barker, Steven A.; Daley, Paul F.; Cozzi, Nicholas V.; Martins, Claudia P. B.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 51; nb. 14; (2008); p. 423 429, View in Reaxys
spectrum; electron impact (EI)
Wang, Yu-Yun; Chen, Chinpiao; Journal of the Chinese Chemical Society; vol. 54; nb. 5; (2007); p. 1363 - 1368, View in Reaxys
Reaxys ID 398142 View in Reaxys
7/12 CAS Registry Number: 38112-90-2 Chemical Name: N,N-Dimethyl-<2-14C>-tryptamin; N,N-Dimethyl-[2-14C]-tryptamin Linear Structure Formula: C11 (14)CH16N2 Molecular Formula: C12H16N2 Molecular Weight: 190.261 Type of Substance: heterocyclic InChI Key: DMULVCHRPCFFGV-FOQJRBATSA-N Note:
N
14CH
NH
Derivative (1) Comment (Derivative)
References
Pikrat: F: 172grad Baxter; Slaytor; Phytochemistry (Elsevier); vol. 11; (1972); p. 2767,2773, View in Reaxys Melting Point (1) 1 of 1
Melting Point [°C]
49
Baxter; Slaytor; Phytochemistry (Elsevier); vol. 11; (1972); p. 2767,2773, View in Reaxys
Reaxys ID 398143 View in Reaxys
8/12 CAS Registry Number: 41953-91-7 Chemical Name: <1-15N>-N,N-Dimethyl-tryptamin; [1-15N]N,N-Dimethyl-tryptamin Linear Structure Formula: C12H16N(15)N Molecular Formula: C12H16N2 Molecular Weight: 189.266 Type of Substance: heterocyclic InChI Key: DMULVCHRPCFFGV-KCKQSJSWSA-N Note:
N
15
NH
Melting Point (1) 1 of 1
Melting Point [°C]
148 - 149
Dmitrevskaya et al.; Chemistry of Heterocyclic Compounds (New York, NY, United States); vol. 9; (1973); p. 476; Khimiya Geterotsiklicheskikh Soedinenii; vol. 9; (1973); p. 516, View in Reaxys
Reaxys ID 7092342 View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
9/12
41/45
2016-06-01 13:02:51
Chemical Name: 3-<(dimethylamino)ethyl>indole-1-d; 3-[(dimethylamino)ethyl]indole-1-d Linear Structure Formula: C12H15DN2 Molecular Formula: C12H16N2 Molecular Weight: 189.264 Type of Substance: heterocyclic InChI Key: DMULVCHRPCFFGV-DYCDLGHISA-N Note:
N
N 2H
Substance Label (1) Label References XIV
Tupitsyn, I. F.; Komarov, V. I.; J. Gen. Chem. USSR (Engl. Transl.); vol. 57; nb. 8; (1987); p. 1826 1835,1632 - 1640, View in Reaxys
Reaxys ID 10240567 View in Reaxys
10/12 Chemical Name: ayahuasca Type of Substance: mixture (composition partially given) Composition: Comp. Name: Tetrahydroharmine; N,N-Dimethyltryptamine; Harmine; Harmaline Note:
No Structure
Pharmacological Data (7) 1 of 7
Comment (Pharmacological Data)
Bioactivities present
Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J.; Journal of Pharmacology and Experimental Therapeutics; vol. 306; nb. 1; (2003); p. 73 - 83, View in Reaxys 2 of 7
Effect (Pharmacological Data)
psychotonic
Species or Test-System (Pharmacological Data)
human
Sex
male and female
Route of Application
peroral
Concentration (Pharmacological Data)
0.125 - 0.5 g
Kind of Dosing (Pharmacological Data)
title substances (contained per kg of body wt: 0.6/0.85 mg DMT, 1.0/1.4 mg harmine, 0.07/0.09 mg harmaline, 0.82/1.16 mg THH for low and high doses, resp.) given as gelatin capsules
Method (Pharmacological Data)
title substances admin. to subjects (n = 18); pre and post 15, 30, 45, 60, 75 min and 1.5, 2, 2.5, 3, 3.5, 4, 6 and 8 h dosing, subjective effects measured by visual analog scales (VAS)
Further Details (Pharmacological Data)
control: placebo (0.75 g lactose); VAS: any effect, good effects, liking, drunken, stimulated, visions, high; DMT: N,N-dimethyltryptamine; THH: tetrahydroharmine
Results
title substances signif. increased VAS scorings between 90 and 120 min; table, diagram
Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J.; Journal of Pharmacology and Experimental Therapeutics; vol. 306; nb. 1; (2003); p. 73 - 83, View in Reaxys 3 of 7
Effect (Pharmacological Data)
psychotonic
Species or Test-System (Pharmacological Data)
human
Sex
male and female
Route of Application
peroral
Concentration (Pharmacological Data)
0.125 - 0.5 g
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
42/45
2016-06-01 13:02:51
Kind of Dosing (Pharmacological Data)
title substances (contained per kg of body wt: 0.6/0.85 mg DMT, 1.0/1.4 mg harmine, 0.07/0.09 mg harmaline, 0.82/1.16 mg THH for low and high doses, resp.) given as gelatin capsules
Method (Pharmacological Data)
title substances admin. to subjects (n = 18); after 4 h, subjective effects measured by Hallucinogen Rating Scale (HRS)
Further Details (Pharmacological Data)
control: placebo (0.75 g lactose); HRS measurements: affect, cognition, somaesthesia, perception, volition, intensity; DMT: N,N-dimethyltryptamine; THH: tetrahydroharmine
Results
title substances induced signif. increase in all HRS for low and high dose, except volition; tables, diagram
Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J.; Journal of Pharmacology and Experimental Therapeutics; vol. 306; nb. 1; (2003); p. 73 - 83, View in Reaxys 4 of 7
Effect (Pharmacological Data)
psychotonic
Species or Test-System (Pharmacological Data)
human
Sex
male and female
Route of Application
peroral
Concentration (Pharmacological Data)
0.125 - 0.5 g
Kind of Dosing (Pharmacological Data)
title substances (contained per kg of body wt: 0.6/0.85 mg DMT, 1.0/1.4 mg harmine, 0.07/0.09 mg harmaline, 0.82/1.16 mg THH for low and high doses, resp.) given as gelatin capsules
Method (Pharmacological Data)
title substances admin. to subjects (n = 18); after 4 h, subjective effects measured by Addiction Research Center Inventory (ARCI)
Further Details (Pharmacological Data)
control: placebo (0.75 g lactose); ARCI scales: morphine-benzedrine group (MBG), pentobarbital-chlorpromazine-alcohol group (PCAG), lysergic acid diethylamide (LSD), benzedrine group (BG) and A scale; DMT: N,N-dimethyltryptamine; THH: tetrahydroharmine
Results
title substances signif. dose-dependently increased stimulatory effects (A scale), euphoria (MBG scale) and somatic symptoms (LSD scale); tables, diagram
Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J.; Journal of Pharmacology and Experimental Therapeutics; vol. 306; nb. 1; (2003); p. 73 - 83, View in Reaxys 5 of 7
Effect (Pharmacological Data)
cardiovascular
Species or Test-System (Pharmacological Data)
human
Sex
male and female
Route of Application
peroral
Concentration (Pharmacological Data)
0.125 - 0.5 g
Kind of Dosing (Pharmacological Data)
title substances (contained per kg of body wt: 0.6/0.85 mg DMT, 1.0/1.4 mg harmine, 0.07/0.09 mg harmaline, 0.82/1.16 mg THH for low and high doses, resp.) given as gelatin capsules
Method (Pharmacological Data)
title substances admin. to subjects (n = 18); cardiovascular parameters measured before and 15, 30, 45, 60, 75, 90, 120, 150, 180, 210 and 240 min after administration using sphygmomanometer cuff
Further Details (Pharmacological Data)
control: placebo (0.75 g lactose); cardiovascular parameters: systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR); DMT: N,N-dimethyltryptamine; THH: tetrahydroharmine
Results
title substances signif. increased DBP at high dose (9 mm Hg at 75 min), SBP and HR increased moderately; diagram, table
Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J.; Journal of Pharmacology and Experimental Therapeutics; vol. 306; nb. 1; (2003); p. 73 - 83, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
43/45
2016-06-01 13:02:51
6 of 7
Effect (Pharmacological Data)
biotransformation
Species or Test-System (Pharmacological Data)
human
Sex
male and female
Route of Application
peroral
Concentration (Pharmacological Data)
0.125 - 0.5 g
Kind of Dosing (Pharmacological Data)
title substances (contained per kg of body wt: 0.6/0.85 mg DMT, 1.0/1.4 mg harmine, 0.07/0.09 mg harmaline, 0.82/1.16 mg THH for low and high doses, resp.) given as gelatin capsules
Method (Pharmacological Data)
title substances admin. to subjects; urine collected in fractions of 0-8, 8-16 and 16-24 h; pH adjusted to 2-4 with 6N HCl; monoamine metabolites (VMA, HVA, 5-HIAA, metanephrine and normetanephrine) quantified by HPLC
Further Details (Pharmacological Data)
control: placebo (0.75 g lactose); VMA: vanillylmandelic acid; HVA: homavanillic acid; 5HIAA: 5-hydroxyindoleacetic acid; DMT: N,N-dimethyltryptamine; THH: tetrahydroharmine
Results
title substances increased the excretion of VMA, HVA and 5-HIAA; levels of metanephrine and normetanephrine increased with dose; table
Comment (Pharmacological Data)
Further metabolite(s)
Metabolite XRN (Pharmacological Data)
2213227; 2213447; 168797
Metabolite (Pharmacological Data)
2-(4'-Hydroxy-3'-methoxyphenyl)-2-hydroxyethanoic acid; 4-hydroxy 3-methoxy phenylacetic acid; 5-hydroxy-1H-indole-3-acetic acid
Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J.; Journal of Pharmacology and Experimental Therapeutics; vol. 306; nb. 1; (2003); p. 73 - 83, View in Reaxys 7 of 7
Effect (Pharmacological Data)
pharmacokinetics
Species or Test-System (Pharmacological Data)
human
Sex
male and female
Route of Application
peroral
Concentration (Pharmacological Data)
0.125 - 0.5 g
Kind of Dosing (Pharmacological Data)
title substances (contained per kg of body wt: 0.6/0.85 mg DMT, 1.0/1.4 mg harmine, 0.07/0.09 mg harmaline, 0.82/1.16 mg THH for low and high doses, resp.) given as gelatin capsules
Method (Pharmacological Data)
title substances admin. to subjects; blood samples drawn before and at 30, 60, 90, 120, 150 min, 3, 4, 6, 8, 24 h after admin.; plasma conc. of DMT, β-carbolines (tetrahydroharmine (THH), harmine, harmaline) and pharmacokinetics (PK) parameters studied
Further Details (Pharmacological Data)
O-demethylated metabolites harmol, harmalol measured; DMT and β-carbolines measured by gas chromatography and HPLC, resp.; DMT: N,N-dimethyltryptamine; PK parameters: Cmax, Tmax, AUC from 0-8 h, clearance, terminal half-life, volume of distribution
Results
title substances increased Cmax, AUC, and Tmax; dose-dependently increased the level of harmol and harmalol; Cmax values for low and high doses were 12.14 ng/ml and 17.44 ng/ml, resp.; diagram, table
Metabolite XRN (Pharmacological Data)
173698; 201180
Metabolite (Pharmacological Data)
Harmol; Harmalol
Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J.; Journal of Pharmacology and Experimental Therapeutics; vol. 306; nb. 1; (2003); p. 73 - 83, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
44/45
2016-06-01 13:02:51
Reaxys ID 24205086 View in Reaxys
11/12 -1 HCl
Chemical Name: N,N-Dimethyltryptamine hydrochloride Linear Structure Formula: C12H16N2*(x)ClH Molecular Formula: C12H16N2*(x)ClH InChI Key: FXCHKLOHTIIVJW-UHFFFAOYSA-N Note:
N
NH
Pharmacological Data (1) 1 of 1
Comment (Pharmacological Data)
Bioactivities present
Whitaker; Seeman; Psychopharmacology; vol. 59; nb. 1; (1978); p. 1 - 5, View in Reaxys
Reaxys ID 25990097 View in Reaxys
12/12 Linear Structure Formula: C12H16N2*H(1+) Molecular Formula: C12H16N2*H Molecular Weight: 189.28 InChI Key: DMULVCHRPCFFGV-UHFFFAOYSA-O Note:
N H+
NH
Pharmacological Data (1) 1 of 1
Comment (Pharmacological Data)
Bioactivities present
Pratuangdejkul; Schneider; Jaudon; Rosilio; Baudoin; Loric; Conti; Launay; Manivet; Current Medicinal Chemistry; vol. 12; nb. 20; (2005); p. 2393 - 2410, View in Reaxys
Copyright © 2016 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
45/45
2016-06-01 13:02:51